TY  - CONF
AU  - Božović, Ana
AU  - Mandušić, Vesna
AU  - Todorović, Lidija
AU  - Krajnović, Milena
AU  - Kožik, Bojana
AU  - Jovanović-Ćupić, Snežana
AU  - Kokanov, Nikola
PY  - 2023
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/12632
AB  - Since the estrogen receptor alpha (ERα), together with the progesterone receptor (PR) and the hercepƟ n receptor 2 (HER-2), are the dominant factors determining the groups of breast cancer (BC) paƟ ents, breast cancer treatment depends on the presence or absence of these three molecules. Approximately 70% of paƟ ents receive hormone treatment targeƟ ng the estrogen receptor alfa, with tamoxifen (selecƟ ve oestrogen receptor modulator) being the fi rst choice as it inhibits further proliferaƟ on of cancer cells. However, 30% of paƟ ents do not respond to exisƟ ng hormone therapy, raising the quesƟ on of new targets and treatment opƟ ons. Non-responders include paƟ ents who have acquired resistance to standard treatment and triple-negaƟ ve breast cancer paƟ ents (TNBC), characterized by the absence of ERα, PR and HER-2. One of the unexplored potenƟ als for treatment is a protein homologue of ERα, estrogen receptor beta (ERβ), as many studies show ERβ expression in ERα-negaƟ ve paƟ ents. The estrogen receptors alpha and beta belong to the superfamily of nuclear receptors, and their dominant ligand is estrogen. When estrogen binds to estrogen receptors, they form dimers (homo or heterodimers) and bind ERE sequences of target genes (estrogen receptor elements). In a heterodimeric state, ERβ can inhibit ERα transacƟ vaƟ on and thus infl uence the signalling pathways. ERα and ERβ are encoded by highly homologous genes (ESR1 and ESR2), resulƟ ng in two highly homologous protein structures. The human ESR2 gene contains eight exons. The last two coding exons of the ESR2 gene are alternaƟ vely spliced encoding ERβ transcripƟ onal variants (ERβ1-5), resulƟ ng in altered C-terminal domains of the ERβ protein. These transcripƟ onal variants can have dominant posiƟ ve or negaƟ ve funcƟ ons or no funcƟ on at all. While ERα is crucial for the growth and proliferaƟ on of breast Ɵ ssue, ERꞵ plays a role in the normal development of breast Ɵ ssue, ovaries, testes, brain and adrenal glands. Study reports show that ERβ has an anƟ proliferaƟ ve, pro-apoptoƟ c and tumour-suppressive funcƟ on. Its funcƟ on in breast development also implies its funcƟ on in tumourigenesis. However, the expression of ERβ mRNA and protein expression is unclear. Various studies on ERα-posiƟ ve tumours show that ERβ is a tumour suppressor. The studies on ERα-negaƟ ve tumours show controversy, whereby ERβ could be proliferaƟ ve or suppressive. ERβ expression is oŌ en associated with smaller tumour size, lower grade and the absence of metastases. In TNBC paƟ ents, the associaƟ on between clinical outcomes and ERβ is unclear. Some studies associate ERβ with prolonged survival, others with shortened survival, while in others, no associaƟ on has been demonstrated. There are many reasons for these contradicƟ ons. The fi rst reason is unprecise methods of measuring ERβ levels, with diff erences in baseline material. In some studies, the amount of ERβ is esƟ mated by quanƟ taƟ ve PCR, while in others, by anƟ bodies. Secondly, the researchers prevalently use non-specifi c anƟ bodies that cannot detect the existence of specifi c ERβ isoforms. ERβ expression changes during BC progression. In the early stages of BC, ERβ levels decrease, while more advanced stages show a complete loss of ERβ. However, some studies report increased ERβ expression in metastaƟ c Ɵ ssues. Researchers should pay parƟ cular aƩ enƟ on to the molecular mechanisms that alter ERβ expression, with epigeneƟ c mechanisms being the most crucial. One of the most important mechanisms for tumour iniƟ aƟ on and development is gene promoter methylaƟ on. DNA methylaƟ on is an inheritable epigeneƟ c modifi caƟ on in which DNA methyltransferases (DNMTs) promote the transfer of the methyl group from S-adenosyl L-methionine (SAM) to 5'-cytosine of the CpG dinucleoƟ de. CpG methylaƟ on is a crucial regulatory mechanism that begins early in embryogenesis. In the promoters of genes central to development, such as housekeeping genes and some Ɵ ssue-specifi c genes, there are unmethylated regions called CpG islands. CpG islands encompass about 500 to several thousands of base pairs, and the CpGdinucleoƟ des within them are more abundant than in the other genome locaƟ ons. CpG islands in coding genes' promoter regions of cancer cells are regularly hypermethylated, causing gene silencing. The silenced genes are commonly tumour suppressor genes, such as ERβ. ERβ gene promoter region contains two exons, exon OK and exon ON. Most studies have been done on ON exon, linking hypermethylaƟ on of ON exon with decreased ERβ expression. IniƟ ally, the researchers noƟ ced ON exon hypermethylaƟ on in prostate cancer, and prostate cancer cell treatment with a demethylaƟ on agent, 5'-AZAC, led to ERβ expression acƟ vaƟ on. Also, during the progression of prostate cancer, a hypermethylaƟ on level increased. These results were consistent with some studies on breast cancer paƟ ents and cell lines. There is scant data on the associaƟ on between ERβ hypermethylaƟ on and surv ival. Usually, studies show correlaƟ ons between ERβ1 expression and survival. The clinical potenƟ al of ERβ promoter methylaƟ on is yet to be examined. AddiƟ onal research on this molecule and its expression mechanisms should determine its predicƟ ve, diagnosƟ c, and treatment potenƟ al.
PB  - Belgrade : Serbian Association for Cancer Research
C3  - Oncology Insights
T1  - Estrogen Receptor Beta promoter methylation as a possible biomarker in breast cancer
IS  - 1
SP  - 26
EP  - 27
UR  - https://hdl.handle.net/21.15107/rcub_vinar_12632
ER  - 

@conference{
author = "Božović, Ana and Mandušić, Vesna and Todorović, Lidija and Krajnović, Milena and Kožik, Bojana and Jovanović-Ćupić, Snežana and Kokanov, Nikola",
year = "2023",
abstract = "Since the estrogen receptor alpha (ERα), together with the progesterone receptor (PR) and the hercepƟ n receptor 2 (HER-2), are the dominant factors determining the groups of breast cancer (BC) paƟ ents, breast cancer treatment depends on the presence or absence of these three molecules. Approximately 70% of paƟ ents receive hormone treatment targeƟ ng the estrogen receptor alfa, with tamoxifen (selecƟ ve oestrogen receptor modulator) being the fi rst choice as it inhibits further proliferaƟ on of cancer cells. However, 30% of paƟ ents do not respond to exisƟ ng hormone therapy, raising the quesƟ on of new targets and treatment opƟ ons. Non-responders include paƟ ents who have acquired resistance to standard treatment and triple-negaƟ ve breast cancer paƟ ents (TNBC), characterized by the absence of ERα, PR and HER-2. One of the unexplored potenƟ als for treatment is a protein homologue of ERα, estrogen receptor beta (ERβ), as many studies show ERβ expression in ERα-negaƟ ve paƟ ents. The estrogen receptors alpha and beta belong to the superfamily of nuclear receptors, and their dominant ligand is estrogen. When estrogen binds to estrogen receptors, they form dimers (homo or heterodimers) and bind ERE sequences of target genes (estrogen receptor elements). In a heterodimeric state, ERβ can inhibit ERα transacƟ vaƟ on and thus infl uence the signalling pathways. ERα and ERβ are encoded by highly homologous genes (ESR1 and ESR2), resulƟ ng in two highly homologous protein structures. The human ESR2 gene contains eight exons. The last two coding exons of the ESR2 gene are alternaƟ vely spliced encoding ERβ transcripƟ onal variants (ERβ1-5), resulƟ ng in altered C-terminal domains of the ERβ protein. These transcripƟ onal variants can have dominant posiƟ ve or negaƟ ve funcƟ ons or no funcƟ on at all. While ERα is crucial for the growth and proliferaƟ on of breast Ɵ ssue, ERꞵ plays a role in the normal development of breast Ɵ ssue, ovaries, testes, brain and adrenal glands. Study reports show that ERβ has an anƟ proliferaƟ ve, pro-apoptoƟ c and tumour-suppressive funcƟ on. Its funcƟ on in breast development also implies its funcƟ on in tumourigenesis. However, the expression of ERβ mRNA and protein expression is unclear. Various studies on ERα-posiƟ ve tumours show that ERβ is a tumour suppressor. The studies on ERα-negaƟ ve tumours show controversy, whereby ERβ could be proliferaƟ ve or suppressive. ERβ expression is oŌ en associated with smaller tumour size, lower grade and the absence of metastases. In TNBC paƟ ents, the associaƟ on between clinical outcomes and ERβ is unclear. Some studies associate ERβ with prolonged survival, others with shortened survival, while in others, no associaƟ on has been demonstrated. There are many reasons for these contradicƟ ons. The fi rst reason is unprecise methods of measuring ERβ levels, with diff erences in baseline material. In some studies, the amount of ERβ is esƟ mated by quanƟ taƟ ve PCR, while in others, by anƟ bodies. Secondly, the researchers prevalently use non-specifi c anƟ bodies that cannot detect the existence of specifi c ERβ isoforms. ERβ expression changes during BC progression. In the early stages of BC, ERβ levels decrease, while more advanced stages show a complete loss of ERβ. However, some studies report increased ERβ expression in metastaƟ c Ɵ ssues. Researchers should pay parƟ cular aƩ enƟ on to the molecular mechanisms that alter ERβ expression, with epigeneƟ c mechanisms being the most crucial. One of the most important mechanisms for tumour iniƟ aƟ on and development is gene promoter methylaƟ on. DNA methylaƟ on is an inheritable epigeneƟ c modifi caƟ on in which DNA methyltransferases (DNMTs) promote the transfer of the methyl group from S-adenosyl L-methionine (SAM) to 5'-cytosine of the CpG dinucleoƟ de. CpG methylaƟ on is a crucial regulatory mechanism that begins early in embryogenesis. In the promoters of genes central to development, such as housekeeping genes and some Ɵ ssue-specifi c genes, there are unmethylated regions called CpG islands. CpG islands encompass about 500 to several thousands of base pairs, and the CpGdinucleoƟ des within them are more abundant than in the other genome locaƟ ons. CpG islands in coding genes' promoter regions of cancer cells are regularly hypermethylated, causing gene silencing. The silenced genes are commonly tumour suppressor genes, such as ERβ. ERβ gene promoter region contains two exons, exon OK and exon ON. Most studies have been done on ON exon, linking hypermethylaƟ on of ON exon with decreased ERβ expression. IniƟ ally, the researchers noƟ ced ON exon hypermethylaƟ on in prostate cancer, and prostate cancer cell treatment with a demethylaƟ on agent, 5'-AZAC, led to ERβ expression acƟ vaƟ on. Also, during the progression of prostate cancer, a hypermethylaƟ on level increased. These results were consistent with some studies on breast cancer paƟ ents and cell lines. There is scant data on the associaƟ on between ERβ hypermethylaƟ on and surv ival. Usually, studies show correlaƟ ons between ERβ1 expression and survival. The clinical potenƟ al of ERβ promoter methylaƟ on is yet to be examined. AddiƟ onal research on this molecule and its expression mechanisms should determine its predicƟ ve, diagnosƟ c, and treatment potenƟ al.",
publisher = "Belgrade : Serbian Association for Cancer Research",
journal = "Oncology Insights",
title = "Estrogen Receptor Beta promoter methylation as a possible biomarker in breast cancer",
number = "1",
pages = "26-27",
url = "https://hdl.handle.net/21.15107/rcub_vinar_12632"
}

Božović, A., Mandušić, V., Todorović, L., Krajnović, M., Kožik, B., Jovanović-Ćupić, S.,& Kokanov, N.. (2023). Estrogen Receptor Beta promoter methylation as a possible biomarker in breast cancer. in Oncology Insights
Belgrade : Serbian Association for Cancer Research.(1), 26-27.
https://hdl.handle.net/21.15107/rcub_vinar_12632

Božović A, Mandušić V, Todorović L, Krajnović M, Kožik B, Jovanović-Ćupić S, Kokanov N. Estrogen Receptor Beta promoter methylation as a possible biomarker in breast cancer. in Oncology Insights. 2023;(1):26-27.
https://hdl.handle.net/21.15107/rcub_vinar_12632 .

Božović, Ana, Mandušić, Vesna, Todorović, Lidija, Krajnović, Milena, Kožik, Bojana, Jovanović-Ćupić, Snežana, Kokanov, Nikola, "Estrogen Receptor Beta promoter methylation as a possible biomarker in breast cancer" in Oncology Insights, no. 1 (2023):26-27,
https://hdl.handle.net/21.15107/rcub_vinar_12632 .

TY  - JOUR
AU  - Krajnović, Milena M.
AU  - Kožik, Bojana
AU  - Božović, Ana M.
AU  - Jovanović-Ćupić, Snežana
PY  - 2023
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/11625
AB  - : Hepatocellular carcinoma (HCC) is one of the most frequent cancers in humans, characterised by a high resistance to conventional chemotherapy, late diagnosis, and a high mortality rate. It is necessary to elucidate the molecular mechanisms involved in hepatocarcinogenesis to improve diagnosis and treatment outcomes. The Runt-related (RUNX) family of transcription factors (RUNX1, RUNX2, and RUNX3) participates in cardinal biological processes and plays paramount roles in the pathogenesis of numerous human malignancies. Their role is often controversial as they can act as oncogenes or tumour suppressors and depends on cellular context. Evidence shows that deregulated RUNX genes may be involved in hepatocarcinogenesis from the earliest to the latest stages. In this review, we summarise the topical evidence on the roles of RUNX gene family members in HCC. We discuss their possible application as non-invasive molecular markers for early diagnosis, prognosis, and development of novel treatment strategies in HCC patients.
T2  - Cells
T1  - Multiple Roles of the RUNX Gene Family in Hepatocellular Carcinoma and Their Potential Clinical Implications
VL  - 12
IS  - 18
SP  - 2303
DO  - 10.3390/cells12182303
ER  - 

@article{
author = "Krajnović, Milena M. and Kožik, Bojana and Božović, Ana M. and Jovanović-Ćupić, Snežana",
year = "2023",
abstract = ": Hepatocellular carcinoma (HCC) is one of the most frequent cancers in humans, characterised by a high resistance to conventional chemotherapy, late diagnosis, and a high mortality rate. It is necessary to elucidate the molecular mechanisms involved in hepatocarcinogenesis to improve diagnosis and treatment outcomes. The Runt-related (RUNX) family of transcription factors (RUNX1, RUNX2, and RUNX3) participates in cardinal biological processes and plays paramount roles in the pathogenesis of numerous human malignancies. Their role is often controversial as they can act as oncogenes or tumour suppressors and depends on cellular context. Evidence shows that deregulated RUNX genes may be involved in hepatocarcinogenesis from the earliest to the latest stages. In this review, we summarise the topical evidence on the roles of RUNX gene family members in HCC. We discuss their possible application as non-invasive molecular markers for early diagnosis, prognosis, and development of novel treatment strategies in HCC patients.",
journal = "Cells",
title = "Multiple Roles of the RUNX Gene Family in Hepatocellular Carcinoma and Their Potential Clinical Implications",
volume = "12",
number = "18",
pages = "2303",
doi = "10.3390/cells12182303"
}

Krajnović, M. M., Kožik, B., Božović, A. M.,& Jovanović-Ćupić, S.. (2023). Multiple Roles of the RUNX Gene Family in Hepatocellular Carcinoma and Their Potential Clinical Implications. in Cells, 12(18), 2303.
https://doi.org/10.3390/cells12182303

Krajnović MM, Kožik B, Božović AM, Jovanović-Ćupić S. Multiple Roles of the RUNX Gene Family in Hepatocellular Carcinoma and Their Potential Clinical Implications. in Cells. 2023;12(18):2303.
doi:10.3390/cells12182303 .

Krajnović, Milena M., Kožik, Bojana, Božović, Ana M., Jovanović-Ćupić, Snežana, "Multiple Roles of the RUNX Gene Family in Hepatocellular Carcinoma and Their Potential Clinical Implications" in Cells, 12, no. 18 (2023):2303,
https://doi.org/10.3390/cells12182303 . .

TY  - JOUR
AU  - Kokanov, Nikola
AU  - Jovanović-Ćupić, Snežana
AU  - Šiljić, Marina
AU  - Ćirković, Valentina
AU  - Petrović, Nina
AU  - Kožik, Bojana
AU  - Krajnović, Milena
PY  - 2023
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/12051
AB  - Variations in the hepatitis C virus (HCV) core sequence have been related to disease progression and response to antiviral therapy. Previously we showed that the methylation status of RASSF1A and p16 genes, and IL28B genotypes affects the response to pegylated interferon/ribavirin (PEG-IFN/RBV) therapy. Herein we investigated whether amino acid (aa) substitutions in the HCV core region alone or in combination with IL28B genotypes and RASSF1A/p16 methylation affect the response to PEG-IFN/RBV therapy and liver disease progression. Among 29 examined patients, we found no association between single aa substitutions and response to therapy. However, we observed that patients with the HCV core aa substitution at position 75 and CT/TT IL28B genotypes were non-responders (NR), (P=0.023). Moreover, these patients had unmethylated RASSF1A. In contrast, most patients (75%) with aa substitutions at position 91 and CC IL28B genotype achieved sustained virologic response (SVR), (P=0.030), and 70% of them had methylated RASSF1A gene. Our results suggest that combined analysis of aa substitutions in the core protein, the IL28B rs12979860 polymorphism, and the methylation status of the RASSF1A gene may help in predicting treatment response to PEG-IFN/RBV in genotype 1b chronic hepatitis C patients.
T2  - Archives of Biological Sciences
T1  - Variability of the HCV core region and host genetic and epigenetic factors can predict the response to pegylated interferon/ribavirin therapy in genotype 1b hepatitis C patients from Serbia
VL  - 75
IS  - 3
SP  - 251
EP  - 262
DO  - 10.2298/ABS230316020K
ER  - 

@article{
author = "Kokanov, Nikola and Jovanović-Ćupić, Snežana and Šiljić, Marina and Ćirković, Valentina and Petrović, Nina and Kožik, Bojana and Krajnović, Milena",
year = "2023",
abstract = "Variations in the hepatitis C virus (HCV) core sequence have been related to disease progression and response to antiviral therapy. Previously we showed that the methylation status of RASSF1A and p16 genes, and IL28B genotypes affects the response to pegylated interferon/ribavirin (PEG-IFN/RBV) therapy. Herein we investigated whether amino acid (aa) substitutions in the HCV core region alone or in combination with IL28B genotypes and RASSF1A/p16 methylation affect the response to PEG-IFN/RBV therapy and liver disease progression. Among 29 examined patients, we found no association between single aa substitutions and response to therapy. However, we observed that patients with the HCV core aa substitution at position 75 and CT/TT IL28B genotypes were non-responders (NR), (P=0.023). Moreover, these patients had unmethylated RASSF1A. In contrast, most patients (75%) with aa substitutions at position 91 and CC IL28B genotype achieved sustained virologic response (SVR), (P=0.030), and 70% of them had methylated RASSF1A gene. Our results suggest that combined analysis of aa substitutions in the core protein, the IL28B rs12979860 polymorphism, and the methylation status of the RASSF1A gene may help in predicting treatment response to PEG-IFN/RBV in genotype 1b chronic hepatitis C patients.",
journal = "Archives of Biological Sciences",
title = "Variability of the HCV core region and host genetic and epigenetic factors can predict the response to pegylated interferon/ribavirin therapy in genotype 1b hepatitis C patients from Serbia",
volume = "75",
number = "3",
pages = "251-262",
doi = "10.2298/ABS230316020K"
}

Kokanov, N., Jovanović-Ćupić, S., Šiljić, M., Ćirković, V., Petrović, N., Kožik, B.,& Krajnović, M.. (2023). Variability of the HCV core region and host genetic and epigenetic factors can predict the response to pegylated interferon/ribavirin therapy in genotype 1b hepatitis C patients from Serbia. in Archives of Biological Sciences, 75(3), 251-262.
https://doi.org/10.2298/ABS230316020K

Kokanov N, Jovanović-Ćupić S, Šiljić M, Ćirković V, Petrović N, Kožik B, Krajnović M. Variability of the HCV core region and host genetic and epigenetic factors can predict the response to pegylated interferon/ribavirin therapy in genotype 1b hepatitis C patients from Serbia. in Archives of Biological Sciences. 2023;75(3):251-262.
doi:10.2298/ABS230316020K .

Kokanov, Nikola, Jovanović-Ćupić, Snežana, Šiljić, Marina, Ćirković, Valentina, Petrović, Nina, Kožik, Bojana, Krajnović, Milena, "Variability of the HCV core region and host genetic and epigenetic factors can predict the response to pegylated interferon/ribavirin therapy in genotype 1b hepatitis C patients from Serbia" in Archives of Biological Sciences, 75, no. 3 (2023):251-262,
https://doi.org/10.2298/ABS230316020K . .

TY  - CONF
AU  - Vučićević, J.
AU  - Čupić, Snežana
AU  - Jauković, M.
AU  - Đurđević, V.
AU  - Stamenović, M.
AU  - Božić, A.
AU  - Janićijević, A.
PY  - 2023
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/11180
PB  - University of Belgrade, Technical Faculty in Bor
C3  - 15th International Mineral Processing and Recycling Conference, IMPRC, 17-19 May 2023, Belgrade, Serbia
T1  - Current state of the quality of the lug river in the municipality of Mladenovac
UR  - https://hdl.handle.net/21.15107/rcub_vinar_11180
ER  - 

@conference{
author = "Vučićević, J. and Čupić, Snežana and Jauković, M. and Đurđević, V. and Stamenović, M. and Božić, A. and Janićijević, A.",
year = "2023",
publisher = "University of Belgrade, Technical Faculty in Bor",
journal = "15th International Mineral Processing and Recycling Conference, IMPRC, 17-19 May 2023, Belgrade, Serbia",
title = "Current state of the quality of the lug river in the municipality of Mladenovac",
url = "https://hdl.handle.net/21.15107/rcub_vinar_11180"
}

Vučićević, J., Čupić, S., Jauković, M., Đurđević, V., Stamenović, M., Božić, A.,& Janićijević, A.. (2023). Current state of the quality of the lug river in the municipality of Mladenovac. in 15th International Mineral Processing and Recycling Conference, IMPRC, 17-19 May 2023, Belgrade, Serbia
University of Belgrade, Technical Faculty in Bor..
https://hdl.handle.net/21.15107/rcub_vinar_11180

Vučićević J, Čupić S, Jauković M, Đurđević V, Stamenović M, Božić A, Janićijević A. Current state of the quality of the lug river in the municipality of Mladenovac. in 15th International Mineral Processing and Recycling Conference, IMPRC, 17-19 May 2023, Belgrade, Serbia. 2023;.
https://hdl.handle.net/21.15107/rcub_vinar_11180 .

Vučićević, J., Čupić, Snežana, Jauković, M., Đurđević, V., Stamenović, M., Božić, A., Janićijević, A., "Current state of the quality of the lug river in the municipality of Mladenovac" in 15th International Mineral Processing and Recycling Conference, IMPRC, 17-19 May 2023, Belgrade, Serbia (2023),
https://hdl.handle.net/21.15107/rcub_vinar_11180 .

TY  - JOUR
AU  - Kokanov, Nikola
AU  - Krajnović, Milena M.
AU  - Jovanović-Ćupić, Snežana P.
AU  - Kožik, Bojana
AU  - Petrović, Nina
AU  - Božović, Ana M.
AU  - Mandušić, Vesna
PY  - 2022
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/10273
AB  - Prevention of chronic hepatitis C (CHC) and its complications is based on antiviral therapy and early detection of reliable molecular markers in persons under risk. We investigated whether the methylation status of RASSF1A and p16 genes, alone or in combination with host and viral factors, affects the response to therapy with pegylated interferon/ribavirin (PEG-IFN/RBV). Methylation-specific polymerase chain reaction (MSP) was used to determine the methylation status of the target promoter sequences of RASSF1A and p16 in circulating-free DNA from the peripheral blood of 49 patients with CHC genotype 1b. The methylation status of the examined genes did not affect the response to therapy. However, the simultaneous presence of either RASSF1A or p16 methylation and the CC genotype of IL28B was significantly related to a sustained virologic response (P=0.009 and P=0.032, respectively). After Bonferroni correction, only the result concerning the RASSF1A gene remained significant (P<0.0125). Methylation of RASSF1A was associated with the CC genotype of the IL28B gene (P=0.024) and a higher viral load (≥400 000 IU/mL, P=0.009). Our results suggest that combined analysis of RASSF1A gene methylation and IL28B rs12979860 polymorphism could potentially help in the prediction of therapy response in CHC genotype 1b patients.
T2  - Archives of Biological Sciences
T1  - RASSF1A and p16 promoter methylation and treatment response in chronic hepatitis C genotype 1b patients treated with pegylated interferon/ribavirin
VL  - 74
IS  - 1
SP  - 57
EP  - 66
DO  - 10.2298/ABS211208004K
ER  - 

@article{
author = "Kokanov, Nikola and Krajnović, Milena M. and Jovanović-Ćupić, Snežana P. and Kožik, Bojana and Petrović, Nina and Božović, Ana M. and Mandušić, Vesna",
year = "2022",
abstract = "Prevention of chronic hepatitis C (CHC) and its complications is based on antiviral therapy and early detection of reliable molecular markers in persons under risk. We investigated whether the methylation status of RASSF1A and p16 genes, alone or in combination with host and viral factors, affects the response to therapy with pegylated interferon/ribavirin (PEG-IFN/RBV). Methylation-specific polymerase chain reaction (MSP) was used to determine the methylation status of the target promoter sequences of RASSF1A and p16 in circulating-free DNA from the peripheral blood of 49 patients with CHC genotype 1b. The methylation status of the examined genes did not affect the response to therapy. However, the simultaneous presence of either RASSF1A or p16 methylation and the CC genotype of IL28B was significantly related to a sustained virologic response (P=0.009 and P=0.032, respectively). After Bonferroni correction, only the result concerning the RASSF1A gene remained significant (P<0.0125). Methylation of RASSF1A was associated with the CC genotype of the IL28B gene (P=0.024) and a higher viral load (≥400 000 IU/mL, P=0.009). Our results suggest that combined analysis of RASSF1A gene methylation and IL28B rs12979860 polymorphism could potentially help in the prediction of therapy response in CHC genotype 1b patients.",
journal = "Archives of Biological Sciences",
title = "RASSF1A and p16 promoter methylation and treatment response in chronic hepatitis C genotype 1b patients treated with pegylated interferon/ribavirin",
volume = "74",
number = "1",
pages = "57-66",
doi = "10.2298/ABS211208004K"
}

Kokanov, N., Krajnović, M. M., Jovanović-Ćupić, S. P., Kožik, B., Petrović, N., Božović, A. M.,& Mandušić, V.. (2022). RASSF1A and p16 promoter methylation and treatment response in chronic hepatitis C genotype 1b patients treated with pegylated interferon/ribavirin. in Archives of Biological Sciences, 74(1), 57-66.
https://doi.org/10.2298/ABS211208004K

Kokanov N, Krajnović MM, Jovanović-Ćupić SP, Kožik B, Petrović N, Božović AM, Mandušić V. RASSF1A and p16 promoter methylation and treatment response in chronic hepatitis C genotype 1b patients treated with pegylated interferon/ribavirin. in Archives of Biological Sciences. 2022;74(1):57-66.
doi:10.2298/ABS211208004K .

Kokanov, Nikola, Krajnović, Milena M., Jovanović-Ćupić, Snežana P., Kožik, Bojana, Petrović, Nina, Božović, Ana M., Mandušić, Vesna, "RASSF1A and p16 promoter methylation and treatment response in chronic hepatitis C genotype 1b patients treated with pegylated interferon/ribavirin" in Archives of Biological Sciences, 74, no. 1 (2022):57-66,
https://doi.org/10.2298/ABS211208004K . .

TY  - JOUR
AU  - Kožik, Bojana
AU  - Krajnović, Milena M.
AU  - Kokanov, Nikola
AU  - Jovanović-Ćupić, Snežana P.
AU  - Božović, Ana M.
AU  - Todorović, Lidija
AU  - Mandušić, Vesna
PY  - 2022
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/10354
AB  - Paper description:Patient responses to standard treatment of advanced stages of rectal carcinoma are variable, which emphasizes the need to define reliable predictive and prognostic molecular parameters.We propose a model of simultaneous analysis of KRAS gene mutation status and p16INK4a and p14ARF gene promoter methylation status in pre-treatment tumor biopsies.The simultaneous presence of p14ARF methylation and KRAS mutation was associated with more aggressive tumor behavior. The concurrent presence of alterations in all three examined genes was associated with shorter overall survival.Combined analysis of examined gene alterations revealed patient subgroups with a distinct pattern of tumor response and disease outcome.Abstract: Current management of locally advanced rectal carcinoma (LARC) involves preoperative chemoradiotherapy (preCRT) before surgery. Despite improved local control rate, the response to preCRT of individual patients is variable and may reflect heterogeneous biological properties among tumors of the same clinical stage. Identifying novel molecular parameters with predictive and/or prognostic value is of great clinical importance for a personalized therapeutic approach. In this study, KRAS mutation status was analyzed by direct sequencing, while methylation-specific polymerase chain reaction (MSP) was used to examine p16INK4a and p14ARF gene methylation status in pretreatment tumor biopsies of 60 patients with LARC. The examined molecular changes of KRAS, p16INK4a and p14ARF genes were mutually independent (p16INK4a/KRAS, P=0.272; p14ARF/KRAS, P=0.923; p16INK4a/p14ARF, P=0.715). However, the simultaneous presence of p14ARF methylation and KRAS mutation was associated with a more frequent appearance of local recurrences and distant metastasis (P=0.027). Moreover, patients with the simultaneous presence of p16INK4a and p14ARF methylation and KRAS mutation had significantly shorter overall survival (P=0.011). The obtained results strongly suggest that combined analyses of examined genetic and epigenetic molecular alterations could contribute to the identification of LARC patient subgroups with more aggressive tumor behavior and worse disease outcome.
T2  - Archives of Biological Sciences
T1  - Combined analysis of KRAS mutation and p16INK4a and p14ARF methylation status in locally advanced rectal carcinoma treated with preoperative chemoradiotherapy
VL  - 74
IS  - 2
SP  - 127
EP  - 134
DO  - 10.2298/ABS220222011K
ER  - 

@article{
author = "Kožik, Bojana and Krajnović, Milena M. and Kokanov, Nikola and Jovanović-Ćupić, Snežana P. and Božović, Ana M. and Todorović, Lidija and Mandušić, Vesna",
year = "2022",
abstract = "Paper description:Patient responses to standard treatment of advanced stages of rectal carcinoma are variable, which emphasizes the need to define reliable predictive and prognostic molecular parameters.We propose a model of simultaneous analysis of KRAS gene mutation status and p16INK4a and p14ARF gene promoter methylation status in pre-treatment tumor biopsies.The simultaneous presence of p14ARF methylation and KRAS mutation was associated with more aggressive tumor behavior. The concurrent presence of alterations in all three examined genes was associated with shorter overall survival.Combined analysis of examined gene alterations revealed patient subgroups with a distinct pattern of tumor response and disease outcome.Abstract: Current management of locally advanced rectal carcinoma (LARC) involves preoperative chemoradiotherapy (preCRT) before surgery. Despite improved local control rate, the response to preCRT of individual patients is variable and may reflect heterogeneous biological properties among tumors of the same clinical stage. Identifying novel molecular parameters with predictive and/or prognostic value is of great clinical importance for a personalized therapeutic approach. In this study, KRAS mutation status was analyzed by direct sequencing, while methylation-specific polymerase chain reaction (MSP) was used to examine p16INK4a and p14ARF gene methylation status in pretreatment tumor biopsies of 60 patients with LARC. The examined molecular changes of KRAS, p16INK4a and p14ARF genes were mutually independent (p16INK4a/KRAS, P=0.272; p14ARF/KRAS, P=0.923; p16INK4a/p14ARF, P=0.715). However, the simultaneous presence of p14ARF methylation and KRAS mutation was associated with a more frequent appearance of local recurrences and distant metastasis (P=0.027). Moreover, patients with the simultaneous presence of p16INK4a and p14ARF methylation and KRAS mutation had significantly shorter overall survival (P=0.011). The obtained results strongly suggest that combined analyses of examined genetic and epigenetic molecular alterations could contribute to the identification of LARC patient subgroups with more aggressive tumor behavior and worse disease outcome.",
journal = "Archives of Biological Sciences",
title = "Combined analysis of KRAS mutation and p16INK4a and p14ARF methylation status in locally advanced rectal carcinoma treated with preoperative chemoradiotherapy",
volume = "74",
number = "2",
pages = "127-134",
doi = "10.2298/ABS220222011K"
}

Kožik, B., Krajnović, M. M., Kokanov, N., Jovanović-Ćupić, S. P., Božović, A. M., Todorović, L.,& Mandušić, V.. (2022). Combined analysis of KRAS mutation and p16INK4a and p14ARF methylation status in locally advanced rectal carcinoma treated with preoperative chemoradiotherapy. in Archives of Biological Sciences, 74(2), 127-134.
https://doi.org/10.2298/ABS220222011K

Kožik B, Krajnović MM, Kokanov N, Jovanović-Ćupić SP, Božović AM, Todorović L, Mandušić V. Combined analysis of KRAS mutation and p16INK4a and p14ARF methylation status in locally advanced rectal carcinoma treated with preoperative chemoradiotherapy. in Archives of Biological Sciences. 2022;74(2):127-134.
doi:10.2298/ABS220222011K .

Kožik, Bojana, Krajnović, Milena M., Kokanov, Nikola, Jovanović-Ćupić, Snežana P., Božović, Ana M., Todorović, Lidija, Mandušić, Vesna, "Combined analysis of KRAS mutation and p16INK4a and p14ARF methylation status in locally advanced rectal carcinoma treated with preoperative chemoradiotherapy" in Archives of Biological Sciences, 74, no. 2 (2022):127-134,
https://doi.org/10.2298/ABS220222011K . .

TY  - CONF
AU  - Kožik, Bojana
AU  - Krajnović, Milena
AU  - Jovanović Ćupić, Snežana
AU  - Kokanov, Nikola
AU  - Božović, Ana
AU  - Todorović, Lidija
AU  - Mandušić, Vesna
PY  - 2021
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/12647
AB  - Background: Rectal cancer represents approximately 30% of cases of colorectal carcinoma and locally advanced stages of rectal cancers (LARC) remain a great clinical challenge due to chemoresistance and high local recurrence rate. The current management of LARC involves neoadjuvant chemoradiotherapy (neoCRT) before surgery. Since only a subset of patients benefit from this preoperative treatment, the development of reliable molecular biomarkers is required. In this retrospective study, we investigated the mutation status of K-ras proto-oncogene, as well as the expression level of apoptosis regulator protein, BCL2, to evaluate their potential predictive role in LARC. Patients and Methods: K-ras gene mutation status was determined by direct sequencing, while BCL2 protein expression was detected immunohistochemically (semi-quantitatively method) in pre-therapeutic and pre-operative biopsy specimens of 61 patients with LARC treated with neoCRT. Results: According to the results of this study, K-ras mutation status and BCL2 expression status were mutually independent events. In general, K-ras mutation status did not affect the response to CRT, while in the group of patients with high BCL2 expression was observed a tendency toward a worse response to the same treatment (p=0.098). However, the subgroup of patients with the simultaneous presence of K-ras mutation and high BCL2 expression showed significantly worse response to neoCRT (p=0.022). Conclusion: Obtained results strongly suggest that combined analyses of molecular aberrations in K-ras proto-oncogene and BCL2 anti-apoptotic protein expression level could have a potential predictive role and important clinical relevance in the identification of LARC patient subgroups, with a distinct pattern of response to neoCRT.
PB  - Belgrade : Serbian Association for Cancer Research (SDIR)
C3  - SDIR- 5 : 5th Congress of the serbian association for cancer research : Book of abstracts
T1  - Potential predictive role of K-ras gene mutation and BCL2 protein expression status in locally advanced rectal cancers treated with neoadjuvant chemoradiotherapy
SP  - 20
EP  - 20
UR  - https://hdl.handle.net/21.15107/rcub_vinar_12647
ER  - 

@conference{
author = "Kožik, Bojana and Krajnović, Milena and Jovanović Ćupić, Snežana and Kokanov, Nikola and Božović, Ana and Todorović, Lidija and Mandušić, Vesna",
year = "2021",
abstract = "Background: Rectal cancer represents approximately 30% of cases of colorectal carcinoma and locally advanced stages of rectal cancers (LARC) remain a great clinical challenge due to chemoresistance and high local recurrence rate. The current management of LARC involves neoadjuvant chemoradiotherapy (neoCRT) before surgery. Since only a subset of patients benefit from this preoperative treatment, the development of reliable molecular biomarkers is required. In this retrospective study, we investigated the mutation status of K-ras proto-oncogene, as well as the expression level of apoptosis regulator protein, BCL2, to evaluate their potential predictive role in LARC. Patients and Methods: K-ras gene mutation status was determined by direct sequencing, while BCL2 protein expression was detected immunohistochemically (semi-quantitatively method) in pre-therapeutic and pre-operative biopsy specimens of 61 patients with LARC treated with neoCRT. Results: According to the results of this study, K-ras mutation status and BCL2 expression status were mutually independent events. In general, K-ras mutation status did not affect the response to CRT, while in the group of patients with high BCL2 expression was observed a tendency toward a worse response to the same treatment (p=0.098). However, the subgroup of patients with the simultaneous presence of K-ras mutation and high BCL2 expression showed significantly worse response to neoCRT (p=0.022). Conclusion: Obtained results strongly suggest that combined analyses of molecular aberrations in K-ras proto-oncogene and BCL2 anti-apoptotic protein expression level could have a potential predictive role and important clinical relevance in the identification of LARC patient subgroups, with a distinct pattern of response to neoCRT.",
publisher = "Belgrade : Serbian Association for Cancer Research (SDIR)",
journal = "SDIR- 5 : 5th Congress of the serbian association for cancer research : Book of abstracts",
title = "Potential predictive role of K-ras gene mutation and BCL2 protein expression status in locally advanced rectal cancers treated with neoadjuvant chemoradiotherapy",
pages = "20-20",
url = "https://hdl.handle.net/21.15107/rcub_vinar_12647"
}

Kožik, B., Krajnović, M., Jovanović Ćupić, S., Kokanov, N., Božović, A., Todorović, L.,& Mandušić, V.. (2021). Potential predictive role of K-ras gene mutation and BCL2 protein expression status in locally advanced rectal cancers treated with neoadjuvant chemoradiotherapy. in SDIR- 5 : 5th Congress of the serbian association for cancer research : Book of abstracts
Belgrade : Serbian Association for Cancer Research (SDIR)., 20-20.
https://hdl.handle.net/21.15107/rcub_vinar_12647

Kožik B, Krajnović M, Jovanović Ćupić S, Kokanov N, Božović A, Todorović L, Mandušić V. Potential predictive role of K-ras gene mutation and BCL2 protein expression status in locally advanced rectal cancers treated with neoadjuvant chemoradiotherapy. in SDIR- 5 : 5th Congress of the serbian association for cancer research : Book of abstracts. 2021;:20-20.
https://hdl.handle.net/21.15107/rcub_vinar_12647 .

Kožik, Bojana, Krajnović, Milena, Jovanović Ćupić, Snežana, Kokanov, Nikola, Božović, Ana, Todorović, Lidija, Mandušić, Vesna, "Potential predictive role of K-ras gene mutation and BCL2 protein expression status in locally advanced rectal cancers treated with neoadjuvant chemoradiotherapy" in SDIR- 5 : 5th Congress of the serbian association for cancer research : Book of abstracts (2021):20-20,
https://hdl.handle.net/21.15107/rcub_vinar_12647 .

TY  - CONF
AU  - Jovanović-Ćupić, Snežana
PY  - 2018
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/13131
PB  - Beograd : Institut za transfuziologiju i hemobiologiju, Vojnomedicinska akademija
C3  - Simpozijum "Analiza nukleotidne sekvence genoma virusa u medicinskoj dijagnostici"
T1  - Korelacija nukleotidnih/proteinskih sekvenci genoma virusa hepatitisa tipa C sa odgovorom na terapiju i progresiju fibroze jetre
SP  - 14
EP  - 14
UR  - https://hdl.handle.net/21.15107/rcub_vinar_13131
ER  - 

@conference{
author = "Jovanović-Ćupić, Snežana",
year = "2018",
publisher = "Beograd : Institut za transfuziologiju i hemobiologiju, Vojnomedicinska akademija",
journal = "Simpozijum "Analiza nukleotidne sekvence genoma virusa u medicinskoj dijagnostici"",
title = "Korelacija nukleotidnih/proteinskih sekvenci genoma virusa hepatitisa tipa C sa odgovorom na terapiju i progresiju fibroze jetre",
pages = "14-14",
url = "https://hdl.handle.net/21.15107/rcub_vinar_13131"
}

Jovanović-Ćupić, S.. (2018). Korelacija nukleotidnih/proteinskih sekvenci genoma virusa hepatitisa tipa C sa odgovorom na terapiju i progresiju fibroze jetre. in Simpozijum "Analiza nukleotidne sekvence genoma virusa u medicinskoj dijagnostici"
Beograd : Institut za transfuziologiju i hemobiologiju, Vojnomedicinska akademija., 14-14.
https://hdl.handle.net/21.15107/rcub_vinar_13131

Jovanović-Ćupić S. Korelacija nukleotidnih/proteinskih sekvenci genoma virusa hepatitisa tipa C sa odgovorom na terapiju i progresiju fibroze jetre. in Simpozijum "Analiza nukleotidne sekvence genoma virusa u medicinskoj dijagnostici". 2018;:14-14.
https://hdl.handle.net/21.15107/rcub_vinar_13131 .

Jovanović-Ćupić, Snežana, "Korelacija nukleotidnih/proteinskih sekvenci genoma virusa hepatitisa tipa C sa odgovorom na terapiju i progresiju fibroze jetre" in Simpozijum "Analiza nukleotidne sekvence genoma virusa u medicinskoj dijagnostici" (2018):14-14,
https://hdl.handle.net/21.15107/rcub_vinar_13131 .

TY  - JOUR
AU  - Kožik, Bojana
AU  - Kokanov, Nikola
AU  - Knežević-Ušaj, Slavica
AU  - Nikolić, Ivan
AU  - Davidović, Radoslav S.
AU  - Jovanović-Ćupić, Snežana P.
AU  - Krajnović, Milena M.
PY  - 2018
UR  - http://www.doiserbia.nb.rs/Article.aspx?ID=0354-46641800030K
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/8002
AB  - Methylation of p16 and p14 genes is a common event in colorectal cancers; however, their exact role in the prediction of patients' outcome is unclear. We conducted this retrospective study to evaluate their potential predictive and/or prognostic roles. Methylation-specific PCR was used to examine the methylation status of p16 and p14 in pretherapeutic and preoperative biopsy specimens of 60 patients with locally advanced rectal cancer. The methylation status of the examined genes did not affect the response to preoperative chemoradiotherapy (CRT), recurrence rate and overall survival. However, patients with a simultaneous presence of either p16 or p14 methylation and high vascular endothelial growth factor (VEGF) expression showed a significantly worse response to CRT (p=0.005 and p=0.038, respectively). Moreover, patients with both p16 methylation and high VEGF expression had significantly shorter overall survival (p=0.010), while no such association was found in patients with p14 methylation and high VEGF expression. On the other hand, a subgroup of patients with p16 methylation and low VEGF and high epidermal growth factor receptor (EGFR) expression showed a significantly better response to CRT (p=0.024). The obtained results point to the importance of p16 and p14 methylation analyses in combination with VEGF and EGFR expression, aimed at better predicting treatment response and patient outcome. © 2018 by the Serbian Biological Society.
T2  - Archives of Biological Sciences
T1  - Methylation status of p16 and p14 genes in locally advanced rectal cancer: Potential clinical implication
VL  - 70
IS  - 4
SP  - 681
EP  - 690
DO  - 10.2298/ABS180316030K
ER  - 

@article{
author = "Kožik, Bojana and Kokanov, Nikola and Knežević-Ušaj, Slavica and Nikolić, Ivan and Davidović, Radoslav S. and Jovanović-Ćupić, Snežana P. and Krajnović, Milena M.",
year = "2018",
abstract = "Methylation of p16 and p14 genes is a common event in colorectal cancers; however, their exact role in the prediction of patients' outcome is unclear. We conducted this retrospective study to evaluate their potential predictive and/or prognostic roles. Methylation-specific PCR was used to examine the methylation status of p16 and p14 in pretherapeutic and preoperative biopsy specimens of 60 patients with locally advanced rectal cancer. The methylation status of the examined genes did not affect the response to preoperative chemoradiotherapy (CRT), recurrence rate and overall survival. However, patients with a simultaneous presence of either p16 or p14 methylation and high vascular endothelial growth factor (VEGF) expression showed a significantly worse response to CRT (p=0.005 and p=0.038, respectively). Moreover, patients with both p16 methylation and high VEGF expression had significantly shorter overall survival (p=0.010), while no such association was found in patients with p14 methylation and high VEGF expression. On the other hand, a subgroup of patients with p16 methylation and low VEGF and high epidermal growth factor receptor (EGFR) expression showed a significantly better response to CRT (p=0.024). The obtained results point to the importance of p16 and p14 methylation analyses in combination with VEGF and EGFR expression, aimed at better predicting treatment response and patient outcome. © 2018 by the Serbian Biological Society.",
journal = "Archives of Biological Sciences",
title = "Methylation status of p16 and p14 genes in locally advanced rectal cancer: Potential clinical implication",
volume = "70",
number = "4",
pages = "681-690",
doi = "10.2298/ABS180316030K"
}

Kožik, B., Kokanov, N., Knežević-Ušaj, S., Nikolić, I., Davidović, R. S., Jovanović-Ćupić, S. P.,& Krajnović, M. M.. (2018). Methylation status of p16 and p14 genes in locally advanced rectal cancer: Potential clinical implication. in Archives of Biological Sciences, 70(4), 681-690.
https://doi.org/10.2298/ABS180316030K

Kožik B, Kokanov N, Knežević-Ušaj S, Nikolić I, Davidović RS, Jovanović-Ćupić SP, Krajnović MM. Methylation status of p16 and p14 genes in locally advanced rectal cancer: Potential clinical implication. in Archives of Biological Sciences. 2018;70(4):681-690.
doi:10.2298/ABS180316030K .

Kožik, Bojana, Kokanov, Nikola, Knežević-Ušaj, Slavica, Nikolić, Ivan, Davidović, Radoslav S., Jovanović-Ćupić, Snežana P., Krajnović, Milena M., "Methylation status of p16 and p14 genes in locally advanced rectal cancer: Potential clinical implication" in Archives of Biological Sciences, 70, no. 4 (2018):681-690,
https://doi.org/10.2298/ABS180316030K . .

TY  - CONF
AU  - Kožik, Bojana
AU  - Kokanov, Nikola
AU  - Knežević-Ušaj, Slavica
AU  - Nikolić, Ivan
AU  - Davidović, Radoslav
AU  - Jovanović Ćupić, Snežana
AU  - Krajnović, Milena
PY  - 2017
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/12805
AB  - Background: Preoperative chemoradiotherapy (CRT) represents the standard treatment for patients with locally advanced rectal cancer. Since only subset of patients has benefit from this preoperative treatment, development of reliable molecular biomarkers is required. In this retrospective study, we investigated methylation status of p16 and p14 tumor suppressor genes in locally advanced rectal cancer, in order to evaluate their potential predictive and prognostic role. Methods: Methylation-specific PCR was used to examine methylation status of p16 and p14 genes in pretherapeutic and preoperative biopsy specimens of 60 patients with locally advanced rectal cancer. Results: Aberrant methylation of p16 and p14 genes was detected in 43.3% (26/60) and 39.6% (23/58) of cases, respectively. In general, p16 and p14 methylation status did not affect the response to CRT, recurrences rate and overall survival. However, patients with simultaneous presence of either p16 or p14 methylation and high vascular endothelial growth factor (VEGF) expression showed significantly worse response to CRT (p = 0.005 and p = 0.038, respectively). In addition, tendency toward more frequent local recurrences and metastasis was observed in cases with concurrent presence of methylation of either p16 or p14 gene and high VEGF expression (p = 0.075 and p = 0.072, respectively), while patients with both of p16 methylation and high VEGF expression had significantly shorter overall survival (p = 0.010). Conclusion: Obtained results strongly suggest the importance of p16 and p14 methylation analyses in combination with other parameters, particularly VEGF expression, in order to better predict treatment response and patient outcome.
PB  - Belgrade : University of Belgrade, Faculty of Biology
C3  - CoMBoS1 - 1st Congress of Molecular Biologists of Serbia with international participation : Book of abstracts
T1  - Combined analysis of p16 and p14 methylation and VEGF expression status could predict more aggressive phenotype of locally advanced rectal cancers
SP  - 100
EP  - 100
UR  - https://hdl.handle.net/21.15107/rcub_vinar_12805
ER  - 

@conference{
author = "Kožik, Bojana and Kokanov, Nikola and Knežević-Ušaj, Slavica and Nikolić, Ivan and Davidović, Radoslav and Jovanović Ćupić, Snežana and Krajnović, Milena",
year = "2017",
abstract = "Background: Preoperative chemoradiotherapy (CRT) represents the standard treatment for patients with locally advanced rectal cancer. Since only subset of patients has benefit from this preoperative treatment, development of reliable molecular biomarkers is required. In this retrospective study, we investigated methylation status of p16 and p14 tumor suppressor genes in locally advanced rectal cancer, in order to evaluate their potential predictive and prognostic role. Methods: Methylation-specific PCR was used to examine methylation status of p16 and p14 genes in pretherapeutic and preoperative biopsy specimens of 60 patients with locally advanced rectal cancer. Results: Aberrant methylation of p16 and p14 genes was detected in 43.3% (26/60) and 39.6% (23/58) of cases, respectively. In general, p16 and p14 methylation status did not affect the response to CRT, recurrences rate and overall survival. However, patients with simultaneous presence of either p16 or p14 methylation and high vascular endothelial growth factor (VEGF) expression showed significantly worse response to CRT (p = 0.005 and p = 0.038, respectively). In addition, tendency toward more frequent local recurrences and metastasis was observed in cases with concurrent presence of methylation of either p16 or p14 gene and high VEGF expression (p = 0.075 and p = 0.072, respectively), while patients with both of p16 methylation and high VEGF expression had significantly shorter overall survival (p = 0.010). Conclusion: Obtained results strongly suggest the importance of p16 and p14 methylation analyses in combination with other parameters, particularly VEGF expression, in order to better predict treatment response and patient outcome.",
publisher = "Belgrade : University of Belgrade, Faculty of Biology",
journal = "CoMBoS1 - 1st Congress of Molecular Biologists of Serbia with international participation : Book of abstracts",
title = "Combined analysis of p16 and p14 methylation and VEGF expression status could predict more aggressive phenotype of locally advanced rectal cancers",
pages = "100-100",
url = "https://hdl.handle.net/21.15107/rcub_vinar_12805"
}

Kožik, B., Kokanov, N., Knežević-Ušaj, S., Nikolić, I., Davidović, R., Jovanović Ćupić, S.,& Krajnović, M.. (2017). Combined analysis of p16 and p14 methylation and VEGF expression status could predict more aggressive phenotype of locally advanced rectal cancers. in CoMBoS1 - 1st Congress of Molecular Biologists of Serbia with international participation : Book of abstracts
Belgrade : University of Belgrade, Faculty of Biology., 100-100.
https://hdl.handle.net/21.15107/rcub_vinar_12805

Kožik B, Kokanov N, Knežević-Ušaj S, Nikolić I, Davidović R, Jovanović Ćupić S, Krajnović M. Combined analysis of p16 and p14 methylation and VEGF expression status could predict more aggressive phenotype of locally advanced rectal cancers. in CoMBoS1 - 1st Congress of Molecular Biologists of Serbia with international participation : Book of abstracts. 2017;:100-100.
https://hdl.handle.net/21.15107/rcub_vinar_12805 .

Kožik, Bojana, Kokanov, Nikola, Knežević-Ušaj, Slavica, Nikolić, Ivan, Davidović, Radoslav, Jovanović Ćupić, Snežana, Krajnović, Milena, "Combined analysis of p16 and p14 methylation and VEGF expression status could predict more aggressive phenotype of locally advanced rectal cancers" in CoMBoS1 - 1st Congress of Molecular Biologists of Serbia with international participation : Book of abstracts (2017):100-100,
https://hdl.handle.net/21.15107/rcub_vinar_12805 .

TY  - JOUR
AU  - Petrović, Nina
AU  - Sami, Ahmad
AU  - Martinović, Jelena
AU  - Zarić, Marina
AU  - Nakashidze, Irina
AU  - Lukić, Silvana
AU  - Jovanović-Ćupić, Snežana P.
PY  - 2017
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/1805
AB  - Background: Breast carcinomas (BC) belong to a heterogeneous group of malignant diseases. Correct categorization of BC based on molecular biomarkers has a very important role in deciding the proper course of therapy for each patient. It has been already shown that the decrease of TIMP metalloproteinase inhibitor 3 (TIMP-3) together with overexpression of microRNA-21 (miR-21) might be involved in the process of BC invasion. This is the first study that examined relationship among miR-21, TIMP-3 mRNA and TIPM-3 protein levels in BC groups formed according to invasiveness. Methods: In this study, we used 46 breast cancer samples. Estrogen and progesterone receptor (ER, PR) protein levels were evaluated by immunohistochemistry (IHC) method. TIMP-3 mRNA expression was examined by two-step real-time quantitative PCR (qRT-PCR). Western blot analysis was performed for 16 samples. Results: Statistically significant differences in TIMP-3 expression levels between invasive groups were discovered in ER positive (ER+) (p = 0.015), Her-2 negative (p = 0.026) subgroups, and patients without lymph-node metastasis (p = 0.039). Interestingly, significant positive correlation was detected between miR-21 and TIMP-3 mRNA levels (P LT 0.001, p = 0.949) in the group of in situ tumors. TIMP-3 mRNA expression levels highly negatively correlated with levels of miR-21 in PR + invasive BCs (p = 0.007, p = -0.641). TIMP-3 protein levels negatively correlated with miR-21 levels in pure invasive BCs. Conclusion: These data suggest that signaling pathways involved in formation and progression of BCs in groups formed according to invasiveness might be different. Our findings propose that TIMP-3 mRNA expression levels could be significant prognostic parameter, but within specific BC subtypes.
T2  - Pathology Research and Practice
T1  - TIMP-3 mRNA expression levels positively correlates with levels of miR-21 in in situ BC and negatively in PR positive invasive BC
VL  - 213
IS  - 10
SP  - 1264
EP  - 1270
DO  - 10.1016/j.prp.2017.08.012
ER  - 

@article{
author = "Petrović, Nina and Sami, Ahmad and Martinović, Jelena and Zarić, Marina and Nakashidze, Irina and Lukić, Silvana and Jovanović-Ćupić, Snežana P.",
year = "2017",
abstract = "Background: Breast carcinomas (BC) belong to a heterogeneous group of malignant diseases. Correct categorization of BC based on molecular biomarkers has a very important role in deciding the proper course of therapy for each patient. It has been already shown that the decrease of TIMP metalloproteinase inhibitor 3 (TIMP-3) together with overexpression of microRNA-21 (miR-21) might be involved in the process of BC invasion. This is the first study that examined relationship among miR-21, TIMP-3 mRNA and TIPM-3 protein levels in BC groups formed according to invasiveness. Methods: In this study, we used 46 breast cancer samples. Estrogen and progesterone receptor (ER, PR) protein levels were evaluated by immunohistochemistry (IHC) method. TIMP-3 mRNA expression was examined by two-step real-time quantitative PCR (qRT-PCR). Western blot analysis was performed for 16 samples. Results: Statistically significant differences in TIMP-3 expression levels between invasive groups were discovered in ER positive (ER+) (p = 0.015), Her-2 negative (p = 0.026) subgroups, and patients without lymph-node metastasis (p = 0.039). Interestingly, significant positive correlation was detected between miR-21 and TIMP-3 mRNA levels (P LT 0.001, p = 0.949) in the group of in situ tumors. TIMP-3 mRNA expression levels highly negatively correlated with levels of miR-21 in PR + invasive BCs (p = 0.007, p = -0.641). TIMP-3 protein levels negatively correlated with miR-21 levels in pure invasive BCs. Conclusion: These data suggest that signaling pathways involved in formation and progression of BCs in groups formed according to invasiveness might be different. Our findings propose that TIMP-3 mRNA expression levels could be significant prognostic parameter, but within specific BC subtypes.",
journal = "Pathology Research and Practice",
title = "TIMP-3 mRNA expression levels positively correlates with levels of miR-21 in in situ BC and negatively in PR positive invasive BC",
volume = "213",
number = "10",
pages = "1264-1270",
doi = "10.1016/j.prp.2017.08.012"
}

Petrović, N., Sami, A., Martinović, J., Zarić, M., Nakashidze, I., Lukić, S.,& Jovanović-Ćupić, S. P.. (2017). TIMP-3 mRNA expression levels positively correlates with levels of miR-21 in in situ BC and negatively in PR positive invasive BC. in Pathology Research and Practice, 213(10), 1264-1270.
https://doi.org/10.1016/j.prp.2017.08.012

Petrović N, Sami A, Martinović J, Zarić M, Nakashidze I, Lukić S, Jovanović-Ćupić SP. TIMP-3 mRNA expression levels positively correlates with levels of miR-21 in in situ BC and negatively in PR positive invasive BC. in Pathology Research and Practice. 2017;213(10):1264-1270.
doi:10.1016/j.prp.2017.08.012 .

Petrović, Nina, Sami, Ahmad, Martinović, Jelena, Zarić, Marina, Nakashidze, Irina, Lukić, Silvana, Jovanović-Ćupić, Snežana P., "TIMP-3 mRNA expression levels positively correlates with levels of miR-21 in in situ BC and negatively in PR positive invasive BC" in Pathology Research and Practice, 213, no. 10 (2017):1264-1270,
https://doi.org/10.1016/j.prp.2017.08.012 . .

TY  - JOUR
AU  - Krajnović, Milena M.
AU  - Marković, Bojana
AU  - Knežević-Ušaj, Slavica
AU  - Nikolic, Ivan
AU  - Stanojevic, Maja
AU  - Nikolić, Valentina
AU  - Siljic, Marina
AU  - Jovanović-Ćupić, Snežana P.
AU  - Dimitrijević, Bogomir B.
PY  - 2016
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/1164
AB  - In this study, we investigated the mutation status of KRAS gene in pretherapeutic and preoperative biopsies in 63 specimens of locally advanced rectal cancers in order to evaluate its potential predictive and/or prognostic role. Regions of interest of KRAS exon 2 were amplified and visualized on 2% agarose gel. Obtained PCR products were subjected to direct sequencing. KRAS mutations were detected in 35% of patients, 91% of which were located in codon 12 and 9% in codon 13. In general, KRAS mutation status did not affect the response to neoadjuvant chemoradiotherapy (CRT). However, patients harboring mutated KRAS gene, simultaneously with high vascular endothelial growth factor (VEGF) expression, exhibited a worse response to CRT (p = 0.030), a more frequent appearance of local recurrences and distant metastasis (p = 0.003), and shorter overall survival (p = 0.001) compared to all others. On the contrary, patients with GGT GT GCT KRAS mutation exhibited a significantly better response to CRT than those with any other type of KRAS mutation (p = 0.017). Moreover, the presence of GGT GT GCT mutation was associated with low VEGF and Ki67 expression (p = 0.012 in both cases), parameters related to less aggressiveness of the disease. Our results suggest that KRAS mutation status could have some predictive and prognostic importance in rectal cancer when analyzed together with other parameters, such as VEGF and Ki67 expression. In addition, it seems that not only the presence but the type of KRAS mutation is important for examining its impact on CRT response. (C) 2016 Elsevier GmbH. All rights reserved.
T2  - Pathology Research and Practice
T1  - Locally advanced rectal cancers with simultaneous occurrence of KRAS mutation and high VEGF expression show invasive characteristics
VL  - 212
IS  - 7
SP  - 598
EP  - 603
DO  - 10.1016/j.prp.2016.02.018
ER  - 

@article{
author = "Krajnović, Milena M. and Marković, Bojana and Knežević-Ušaj, Slavica and Nikolic, Ivan and Stanojevic, Maja and Nikolić, Valentina and Siljic, Marina and Jovanović-Ćupić, Snežana P. and Dimitrijević, Bogomir B.",
year = "2016",
abstract = "In this study, we investigated the mutation status of KRAS gene in pretherapeutic and preoperative biopsies in 63 specimens of locally advanced rectal cancers in order to evaluate its potential predictive and/or prognostic role. Regions of interest of KRAS exon 2 were amplified and visualized on 2% agarose gel. Obtained PCR products were subjected to direct sequencing. KRAS mutations were detected in 35% of patients, 91% of which were located in codon 12 and 9% in codon 13. In general, KRAS mutation status did not affect the response to neoadjuvant chemoradiotherapy (CRT). However, patients harboring mutated KRAS gene, simultaneously with high vascular endothelial growth factor (VEGF) expression, exhibited a worse response to CRT (p = 0.030), a more frequent appearance of local recurrences and distant metastasis (p = 0.003), and shorter overall survival (p = 0.001) compared to all others. On the contrary, patients with GGT GT GCT KRAS mutation exhibited a significantly better response to CRT than those with any other type of KRAS mutation (p = 0.017). Moreover, the presence of GGT GT GCT mutation was associated with low VEGF and Ki67 expression (p = 0.012 in both cases), parameters related to less aggressiveness of the disease. Our results suggest that KRAS mutation status could have some predictive and prognostic importance in rectal cancer when analyzed together with other parameters, such as VEGF and Ki67 expression. In addition, it seems that not only the presence but the type of KRAS mutation is important for examining its impact on CRT response. (C) 2016 Elsevier GmbH. All rights reserved.",
journal = "Pathology Research and Practice",
title = "Locally advanced rectal cancers with simultaneous occurrence of KRAS mutation and high VEGF expression show invasive characteristics",
volume = "212",
number = "7",
pages = "598-603",
doi = "10.1016/j.prp.2016.02.018"
}

Krajnović, M. M., Marković, B., Knežević-Ušaj, S., Nikolic, I., Stanojevic, M., Nikolić, V., Siljic, M., Jovanović-Ćupić, S. P.,& Dimitrijević, B. B.. (2016). Locally advanced rectal cancers with simultaneous occurrence of KRAS mutation and high VEGF expression show invasive characteristics. in Pathology Research and Practice, 212(7), 598-603.
https://doi.org/10.1016/j.prp.2016.02.018

Krajnović MM, Marković B, Knežević-Ušaj S, Nikolic I, Stanojevic M, Nikolić V, Siljic M, Jovanović-Ćupić SP, Dimitrijević BB. Locally advanced rectal cancers with simultaneous occurrence of KRAS mutation and high VEGF expression show invasive characteristics. in Pathology Research and Practice. 2016;212(7):598-603.
doi:10.1016/j.prp.2016.02.018 .

Krajnović, Milena M., Marković, Bojana, Knežević-Ušaj, Slavica, Nikolic, Ivan, Stanojevic, Maja, Nikolić, Valentina, Siljic, Marina, Jovanović-Ćupić, Snežana P., Dimitrijević, Bogomir B., "Locally advanced rectal cancers with simultaneous occurrence of KRAS mutation and high VEGF expression show invasive characteristics" in Pathology Research and Practice, 212, no. 7 (2016):598-603,
https://doi.org/10.1016/j.prp.2016.02.018 . .

TY  - JOUR
AU  - Jovanović-Ćupić, Snežana P.
AU  - Glišić, Sanja
AU  - Stanojevic, Maja
AU  - Nozic, Darko
AU  - Petrović, Nina
AU  - Mandušić, Vesna
AU  - Krajnović, Milena M.
PY  - 2016
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/1032
AB  - The goal of this study was to identify host and viral factors affecting the response to pegylated interferon/ribavirin (PEG-IFN/RBV) treatment in patients with chronic hepatitis C genotype 1b. Baseline characteristics of the patients and sequences within the p7 region were analyzed in pre-treatment serum samples from 53 individuals with chronic hepatitis C genotype 1b and related to the outcome of therapy. We found a significant correlation between age and response to therapy (p LT 0.001). Furthermore, the pre-treatment viral load was closely associated with the stage of liver fibrosis (p LT 0.001). The presence of fewer than 4 mutations and age above 40 were significantly associated with non-response (NR) (p LT 0.001). Our findings may be useful for estimating the likelihood of achieving a sustained virologic response (SVR) in patients who are chronically infected with hepatitis C virus genotype 1b.
PB  - Springer
T2  - Archives of Virology
T1  - The influence of host factors and sequence variability of the p7 region on the response to pegylated interferon/ribavirin therapy for chronic hepatitis C genotype 1b in patients from Serbia
VL  - 161
IS  - 5
SP  - 1189
EP  - 1198
DO  - 10.1007/s00705-016-2777-z
ER  - 

@article{
author = "Jovanović-Ćupić, Snežana P. and Glišić, Sanja and Stanojevic, Maja and Nozic, Darko and Petrović, Nina and Mandušić, Vesna and Krajnović, Milena M.",
year = "2016",
abstract = "The goal of this study was to identify host and viral factors affecting the response to pegylated interferon/ribavirin (PEG-IFN/RBV) treatment in patients with chronic hepatitis C genotype 1b. Baseline characteristics of the patients and sequences within the p7 region were analyzed in pre-treatment serum samples from 53 individuals with chronic hepatitis C genotype 1b and related to the outcome of therapy. We found a significant correlation between age and response to therapy (p LT 0.001). Furthermore, the pre-treatment viral load was closely associated with the stage of liver fibrosis (p LT 0.001). The presence of fewer than 4 mutations and age above 40 were significantly associated with non-response (NR) (p LT 0.001). Our findings may be useful for estimating the likelihood of achieving a sustained virologic response (SVR) in patients who are chronically infected with hepatitis C virus genotype 1b.",
publisher = "Springer",
journal = "Archives of Virology",
title = "The influence of host factors and sequence variability of the p7 region on the response to pegylated interferon/ribavirin therapy for chronic hepatitis C genotype 1b in patients from Serbia",
volume = "161",
number = "5",
pages = "1189-1198",
doi = "10.1007/s00705-016-2777-z"
}

Jovanović-Ćupić, S. P., Glišić, S., Stanojevic, M., Nozic, D., Petrović, N., Mandušić, V.,& Krajnović, M. M.. (2016). The influence of host factors and sequence variability of the p7 region on the response to pegylated interferon/ribavirin therapy for chronic hepatitis C genotype 1b in patients from Serbia. in Archives of Virology
Springer., 161(5), 1189-1198.
https://doi.org/10.1007/s00705-016-2777-z

Jovanović-Ćupić SP, Glišić S, Stanojevic M, Nozic D, Petrović N, Mandušić V, Krajnović MM. The influence of host factors and sequence variability of the p7 region on the response to pegylated interferon/ribavirin therapy for chronic hepatitis C genotype 1b in patients from Serbia. in Archives of Virology. 2016;161(5):1189-1198.
doi:10.1007/s00705-016-2777-z .

Jovanović-Ćupić, Snežana P., Glišić, Sanja, Stanojevic, Maja, Nozic, Darko, Petrović, Nina, Mandušić, Vesna, Krajnović, Milena M., "The influence of host factors and sequence variability of the p7 region on the response to pegylated interferon/ribavirin therapy for chronic hepatitis C genotype 1b in patients from Serbia" in Archives of Virology, 161, no. 5 (2016):1189-1198,
https://doi.org/10.1007/s00705-016-2777-z . .

TY  - JOUR
AU  - Petrović, Nina
AU  - Davidović, Radoslav S.
AU  - Jovanović-Ćupić, Snežana P.
AU  - Krajnović, Milena M.
AU  - Lukić, Silvana
AU  - Petrović, Milan
AU  - Roganović, Jelena
PY  - 2016
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/1308
AB  - Breast cancer (BC) is a heterogeneous group of diseases that still represents a major cause of death in the female population. MicroRNAs (miRNAs, miRs), such as miR-221 and miR-222, have been shown to be involved in BC pathology by acting via its target genes such as tissue inhibitor of metalloproteinase 3 (TIMP3). The main goals of this study were to find differences in miR-221/222 levels of expression in BC groups based on invasiveness, and to investigate the association with estrogen receptor (ER), TIMP3 messenger RNA (mRNA) levels, and clinicopathological characteristics of patients and tumors. In this study, we measured levels of miR-221/222 in 63 breast tissue samples by quantitative reverse transcription-polymerase chain reaction (qRT-PCR) using TaqMan(A (R)) technology and immunohistochemistry. miR-221/222 levels varied significantly across groups based on invasiveness (P LT 0.001). In in situ tumors, miR-221 and miR-222 were negatively associated with ER (P = 0.001, r = -0.714, and P = 0.013, r = -0.585, respectively). In invasive breast carcinomas associated with non-invasive tumors, miR-222 was inversely associated with ER (P = 0.039, r = -0.620). Pure invasive BCs showed a positive correlation of miR-221 and miR-222 with TIMP3 mRNA levels (P = 0.008, r = 0.508, and P = 0.010, r = 0.497, respectively). An increase in miR-221/222 might be an important event for in situ carcinoma formation, and miR-221/222 may be important molecules that highlight potential differences between invasive breast carcinomas associated with non-invasive and pure invasive BCs.
T2  - Molecular Diagnosis and Therapy
T1  - Changes in miR-221/222 Levels in Invasive and In Situ Carcinomas of the Breast: Differences in Association with Estrogen Receptor and TIMP3 Expression Levels
VL  - 20
IS  - 6
SP  - 603
EP  - 615
DO  - 10.1007/s40291-016-0230-3
ER  - 

@article{
author = "Petrović, Nina and Davidović, Radoslav S. and Jovanović-Ćupić, Snežana P. and Krajnović, Milena M. and Lukić, Silvana and Petrović, Milan and Roganović, Jelena",
year = "2016",
abstract = "Breast cancer (BC) is a heterogeneous group of diseases that still represents a major cause of death in the female population. MicroRNAs (miRNAs, miRs), such as miR-221 and miR-222, have been shown to be involved in BC pathology by acting via its target genes such as tissue inhibitor of metalloproteinase 3 (TIMP3). The main goals of this study were to find differences in miR-221/222 levels of expression in BC groups based on invasiveness, and to investigate the association with estrogen receptor (ER), TIMP3 messenger RNA (mRNA) levels, and clinicopathological characteristics of patients and tumors. In this study, we measured levels of miR-221/222 in 63 breast tissue samples by quantitative reverse transcription-polymerase chain reaction (qRT-PCR) using TaqMan(A (R)) technology and immunohistochemistry. miR-221/222 levels varied significantly across groups based on invasiveness (P LT 0.001). In in situ tumors, miR-221 and miR-222 were negatively associated with ER (P = 0.001, r = -0.714, and P = 0.013, r = -0.585, respectively). In invasive breast carcinomas associated with non-invasive tumors, miR-222 was inversely associated with ER (P = 0.039, r = -0.620). Pure invasive BCs showed a positive correlation of miR-221 and miR-222 with TIMP3 mRNA levels (P = 0.008, r = 0.508, and P = 0.010, r = 0.497, respectively). An increase in miR-221/222 might be an important event for in situ carcinoma formation, and miR-221/222 may be important molecules that highlight potential differences between invasive breast carcinomas associated with non-invasive and pure invasive BCs.",
journal = "Molecular Diagnosis and Therapy",
title = "Changes in miR-221/222 Levels in Invasive and In Situ Carcinomas of the Breast: Differences in Association with Estrogen Receptor and TIMP3 Expression Levels",
volume = "20",
number = "6",
pages = "603-615",
doi = "10.1007/s40291-016-0230-3"
}

Petrović, N., Davidović, R. S., Jovanović-Ćupić, S. P., Krajnović, M. M., Lukić, S., Petrović, M.,& Roganović, J.. (2016). Changes in miR-221/222 Levels in Invasive and In Situ Carcinomas of the Breast: Differences in Association with Estrogen Receptor and TIMP3 Expression Levels. in Molecular Diagnosis and Therapy, 20(6), 603-615.
https://doi.org/10.1007/s40291-016-0230-3

Petrović N, Davidović RS, Jovanović-Ćupić SP, Krajnović MM, Lukić S, Petrović M, Roganović J. Changes in miR-221/222 Levels in Invasive and In Situ Carcinomas of the Breast: Differences in Association with Estrogen Receptor and TIMP3 Expression Levels. in Molecular Diagnosis and Therapy. 2016;20(6):603-615.
doi:10.1007/s40291-016-0230-3 .

Petrović, Nina, Davidović, Radoslav S., Jovanović-Ćupić, Snežana P., Krajnović, Milena M., Lukić, Silvana, Petrović, Milan, Roganović, Jelena, "Changes in miR-221/222 Levels in Invasive and In Situ Carcinomas of the Breast: Differences in Association with Estrogen Receptor and TIMP3 Expression Levels" in Molecular Diagnosis and Therapy, 20, no. 6 (2016):603-615,
https://doi.org/10.1007/s40291-016-0230-3 . .

TY  - CONF
AU  - Šami, A.
AU  - Petrović, Nina
AU  - Mandušić, Vesna
AU  - Todorović, Lidija
AU  - Jovanović-Ćupić, Snežana
AU  - Stanojević, Boban
AU  - Dimitrijević, Bogomir
PY  - 2015
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/12453
C3  - 1st Belgrade International Molecular Life Science Conference for Students : Abstract book & Program
T1  - Tissue Inhibitor of Metalloproteinase 3 (TIMP3) mRNA levels significantly differ in three breast cancer groups formed according to its invasiveness and normal breast cancer samples
SP  - 30
EP  - 30
UR  - https://hdl.handle.net/21.15107/rcub_vinar_12453
ER  - 

@conference{
author = "Šami, A. and Petrović, Nina and Mandušić, Vesna and Todorović, Lidija and Jovanović-Ćupić, Snežana and Stanojević, Boban and Dimitrijević, Bogomir",
year = "2015",
journal = "1st Belgrade International Molecular Life Science Conference for Students : Abstract book & Program",
title = "Tissue Inhibitor of Metalloproteinase 3 (TIMP3) mRNA levels significantly differ in three breast cancer groups formed according to its invasiveness and normal breast cancer samples",
pages = "30-30",
url = "https://hdl.handle.net/21.15107/rcub_vinar_12453"
}

Šami, A., Petrović, N., Mandušić, V., Todorović, L., Jovanović-Ćupić, S., Stanojević, B.,& Dimitrijević, B.. (2015). Tissue Inhibitor of Metalloproteinase 3 (TIMP3) mRNA levels significantly differ in three breast cancer groups formed according to its invasiveness and normal breast cancer samples. in 1st Belgrade International Molecular Life Science Conference for Students : Abstract book & Program, 30-30.
https://hdl.handle.net/21.15107/rcub_vinar_12453

Šami A, Petrović N, Mandušić V, Todorović L, Jovanović-Ćupić S, Stanojević B, Dimitrijević B. Tissue Inhibitor of Metalloproteinase 3 (TIMP3) mRNA levels significantly differ in three breast cancer groups formed according to its invasiveness and normal breast cancer samples. in 1st Belgrade International Molecular Life Science Conference for Students : Abstract book & Program. 2015;:30-30.
https://hdl.handle.net/21.15107/rcub_vinar_12453 .

Šami, A., Petrović, Nina, Mandušić, Vesna, Todorović, Lidija, Jovanović-Ćupić, Snežana, Stanojević, Boban, Dimitrijević, Bogomir, "Tissue Inhibitor of Metalloproteinase 3 (TIMP3) mRNA levels significantly differ in three breast cancer groups formed according to its invasiveness and normal breast cancer samples" in 1st Belgrade International Molecular Life Science Conference for Students : Abstract book & Program (2015):30-30,
https://hdl.handle.net/21.15107/rcub_vinar_12453 .

TY  - CONF
AU  - Radulović, Olga
AU  - Jovanović-Ćupić, Snežana
AU  - Krajnović, Milena
AU  - Božović, Ana
AU  - Marković, Bojana
AU  - Kokanov, Nikola
AU  - Petrović, Nina
PY  - 2015
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/12452
C3  - 1st Belgrade International Molecular Life Science Conference for Students : Abstract book & Program
T1  - IDC-DCIS high-miR-21/Her-2 positive and pure IDC high-miR-21/ER+/PR+ tumors might have therapeutically challenging phenotypes for future anti-miR-21 therapy
UR  - https://hdl.handle.net/21.15107/rcub_vinar_12452
ER  - 

@conference{
author = "Radulović, Olga and Jovanović-Ćupić, Snežana and Krajnović, Milena and Božović, Ana and Marković, Bojana and Kokanov, Nikola and Petrović, Nina",
year = "2015",
journal = "1st Belgrade International Molecular Life Science Conference for Students : Abstract book & Program",
title = "IDC-DCIS high-miR-21/Her-2 positive and pure IDC high-miR-21/ER+/PR+ tumors might have therapeutically challenging phenotypes for future anti-miR-21 therapy",
url = "https://hdl.handle.net/21.15107/rcub_vinar_12452"
}

Radulović, O., Jovanović-Ćupić, S., Krajnović, M., Božović, A., Marković, B., Kokanov, N.,& Petrović, N.. (2015). IDC-DCIS high-miR-21/Her-2 positive and pure IDC high-miR-21/ER+/PR+ tumors might have therapeutically challenging phenotypes for future anti-miR-21 therapy. in 1st Belgrade International Molecular Life Science Conference for Students : Abstract book & Program.
https://hdl.handle.net/21.15107/rcub_vinar_12452

Radulović O, Jovanović-Ćupić S, Krajnović M, Božović A, Marković B, Kokanov N, Petrović N. IDC-DCIS high-miR-21/Her-2 positive and pure IDC high-miR-21/ER+/PR+ tumors might have therapeutically challenging phenotypes for future anti-miR-21 therapy. in 1st Belgrade International Molecular Life Science Conference for Students : Abstract book & Program. 2015;.
https://hdl.handle.net/21.15107/rcub_vinar_12452 .

Radulović, Olga, Jovanović-Ćupić, Snežana, Krajnović, Milena, Božović, Ana, Marković, Bojana, Kokanov, Nikola, Petrović, Nina, "IDC-DCIS high-miR-21/Her-2 positive and pure IDC high-miR-21/ER+/PR+ tumors might have therapeutically challenging phenotypes for future anti-miR-21 therapy" in 1st Belgrade International Molecular Life Science Conference for Students : Abstract book & Program (2015),
https://hdl.handle.net/21.15107/rcub_vinar_12452 .

TY  - JOUR
AU  - Petrović, Nina
AU  - Jovanović-Ćupić, Snežana P.
AU  - Brajušković, Goran
AU  - Lukić, Silvana
AU  - Roganović, Jelena
AU  - Krajnović, Milena M.
AU  - Mandušić, Vesna
PY  - 2015
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/862
AB  - Invasive ductal carcinomas with a non-invasive component (IDC-DCIS) are classified as a group of invasive breast carcinomas, together with pure invasive ductal carcinomas of the breast (IDC). MicroRNA-21 (miR-21) has been characterized as a factor of breast cancer invasiveness, however the difference in miR-21 expression levels between IDC-DCIS and pure IDC tumors and the correlations with standard diagnostic and prognostic parameters inside the IDC-DCIS group are unknown. Our aim was to determine if miR-21 had the ability to distinguish these two invasive breast cancer groups. Levels of miR-21 expression were measured by a stem-loop quantitative Real-Time PCR (RT-qPCR) method. Expression levels of estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor 2 (Her-2) and proliferative index Ki-67 were evaluated by immunohistochemistry. IDC-DCIS tumors had significantly lower levels of miR-21 expression in grade 2 (P=0.003, Mann-Whitney U test), ER positive (P=0.025, Mann-Whitney U test) and PR positive tumors (P=0.024, Mann-Whitney U test) than pure IDCs. miR-21 levels showed a different pattern of expression in IDC-DCIS compared to IDC tumors, which is based on the difference in miR-21 expression between Her-2 negative and Her-2 positive IDC-DCIS tumors (P=0.030, Mann-Whitney U test) and high negative correlation of miR-21 levels with PR levels (rho=-0.886, P=0.006, Spearman correlation). According to our results, IDC-DCIS breast carcinomas act in a different manner in pure IDC tumors with regard to the relations between miR-21 expression levels and the standard diagnostic and prognostic parameters, such as Her-2 status, ER and PR status and protein levels.
T2  - Archives of Biological Sciences
T1  - Micro Rna-21 Expression Levels in Invasive Breast Carcinoma with a Non-Invasive Component
VL  - 67
IS  - 4
SP  - 1285
EP  - 1295
DO  - 10.2298/ABS150327105P
ER  - 

@article{
author = "Petrović, Nina and Jovanović-Ćupić, Snežana P. and Brajušković, Goran and Lukić, Silvana and Roganović, Jelena and Krajnović, Milena M. and Mandušić, Vesna",
year = "2015",
abstract = "Invasive ductal carcinomas with a non-invasive component (IDC-DCIS) are classified as a group of invasive breast carcinomas, together with pure invasive ductal carcinomas of the breast (IDC). MicroRNA-21 (miR-21) has been characterized as a factor of breast cancer invasiveness, however the difference in miR-21 expression levels between IDC-DCIS and pure IDC tumors and the correlations with standard diagnostic and prognostic parameters inside the IDC-DCIS group are unknown. Our aim was to determine if miR-21 had the ability to distinguish these two invasive breast cancer groups. Levels of miR-21 expression were measured by a stem-loop quantitative Real-Time PCR (RT-qPCR) method. Expression levels of estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor 2 (Her-2) and proliferative index Ki-67 were evaluated by immunohistochemistry. IDC-DCIS tumors had significantly lower levels of miR-21 expression in grade 2 (P=0.003, Mann-Whitney U test), ER positive (P=0.025, Mann-Whitney U test) and PR positive tumors (P=0.024, Mann-Whitney U test) than pure IDCs. miR-21 levels showed a different pattern of expression in IDC-DCIS compared to IDC tumors, which is based on the difference in miR-21 expression between Her-2 negative and Her-2 positive IDC-DCIS tumors (P=0.030, Mann-Whitney U test) and high negative correlation of miR-21 levels with PR levels (rho=-0.886, P=0.006, Spearman correlation). According to our results, IDC-DCIS breast carcinomas act in a different manner in pure IDC tumors with regard to the relations between miR-21 expression levels and the standard diagnostic and prognostic parameters, such as Her-2 status, ER and PR status and protein levels.",
journal = "Archives of Biological Sciences",
title = "Micro Rna-21 Expression Levels in Invasive Breast Carcinoma with a Non-Invasive Component",
volume = "67",
number = "4",
pages = "1285-1295",
doi = "10.2298/ABS150327105P"
}

Petrović, N., Jovanović-Ćupić, S. P., Brajušković, G., Lukić, S., Roganović, J., Krajnović, M. M.,& Mandušić, V.. (2015). Micro Rna-21 Expression Levels in Invasive Breast Carcinoma with a Non-Invasive Component. in Archives of Biological Sciences, 67(4), 1285-1295.
https://doi.org/10.2298/ABS150327105P

Petrović N, Jovanović-Ćupić SP, Brajušković G, Lukić S, Roganović J, Krajnović MM, Mandušić V. Micro Rna-21 Expression Levels in Invasive Breast Carcinoma with a Non-Invasive Component. in Archives of Biological Sciences. 2015;67(4):1285-1295.
doi:10.2298/ABS150327105P .

Petrović, Nina, Jovanović-Ćupić, Snežana P., Brajušković, Goran, Lukić, Silvana, Roganović, Jelena, Krajnović, Milena M., Mandušić, Vesna, "Micro Rna-21 Expression Levels in Invasive Breast Carcinoma with a Non-Invasive Component" in Archives of Biological Sciences, 67, no. 4 (2015):1285-1295,
https://doi.org/10.2298/ABS150327105P . .

TY  - JOUR
AU  - Bojić, Tijana
AU  - Milovanović, Branislav
AU  - Jovanović-Ćupić, Snežana P.
PY  - 2015
UR  - http://www.archivesofmedicine.com/abstract/genetic-polymorphisms-of-neurocardiovascular-disorders-6481.html
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/8409
AB  - The autonomic nervous control of cardiovascular (CV) system plays a major role in the adaptation of the organism to the changes in external and internal environment. It’s dysfunction is the major pathophysiological factor in the development of neurocardiovascular diseases. The aim of this review is to present the state of the art on the role of candidate gene polymorphisms of the molecules in the signaling chain of neurocardiovascular transmission in neurocardiovascular diseases. Neurocardiovascular disorders can be classified as sympathetic vs. vagally mediated disorders, though in many disorders both systems are dysfunctional. A number of molecules along the signaling pathway can be functionally modified and be the background of the predisposition, faster progression or complicated form of the disease. When the disease is the consequence of the joined parasympathetic and sympathetic nervous system disequilibrium, the focus of neurogenetic research should be on molecules providing the cross-talk between the two systems: on intercellular and intracellular level and on the level of the signaling process integration. An aggregation of positive results for the association between certain genes and different neurocardiovascular phenotypes pointed on a specific "neurocardiovascular genetic hotspots". Identification of these genes could be of particular interest as a diagnostic tool in the clustered form of neurocardiovascular diseases. New data obtained from neurogenetic approach will improve the disease outcome by gene, pharmacologic and behavioral modulation of the autonomic nervous system.
T2  - Archives of Medicine
T1  - Genetic Polymorphisms of Neurocardiovascular Disorders
VL  - 7
IS  - 2
UR  - https://hdl.handle.net/21.15107/rcub_vinar_8409
ER  - 

@article{
author = "Bojić, Tijana and Milovanović, Branislav and Jovanović-Ćupić, Snežana P.",
year = "2015",
abstract = "The autonomic nervous control of cardiovascular (CV) system plays a major role in the adaptation of the organism to the changes in external and internal environment. It’s dysfunction is the major pathophysiological factor in the development of neurocardiovascular diseases. The aim of this review is to present the state of the art on the role of candidate gene polymorphisms of the molecules in the signaling chain of neurocardiovascular transmission in neurocardiovascular diseases. Neurocardiovascular disorders can be classified as sympathetic vs. vagally mediated disorders, though in many disorders both systems are dysfunctional. A number of molecules along the signaling pathway can be functionally modified and be the background of the predisposition, faster progression or complicated form of the disease. When the disease is the consequence of the joined parasympathetic and sympathetic nervous system disequilibrium, the focus of neurogenetic research should be on molecules providing the cross-talk between the two systems: on intercellular and intracellular level and on the level of the signaling process integration. An aggregation of positive results for the association between certain genes and different neurocardiovascular phenotypes pointed on a specific "neurocardiovascular genetic hotspots". Identification of these genes could be of particular interest as a diagnostic tool in the clustered form of neurocardiovascular diseases. New data obtained from neurogenetic approach will improve the disease outcome by gene, pharmacologic and behavioral modulation of the autonomic nervous system.",
journal = "Archives of Medicine",
title = "Genetic Polymorphisms of Neurocardiovascular Disorders",
volume = "7",
number = "2",
url = "https://hdl.handle.net/21.15107/rcub_vinar_8409"
}

Bojić, T., Milovanović, B.,& Jovanović-Ćupić, S. P.. (2015). Genetic Polymorphisms of Neurocardiovascular Disorders. in Archives of Medicine, 7(2).
https://hdl.handle.net/21.15107/rcub_vinar_8409

Bojić T, Milovanović B, Jovanović-Ćupić SP. Genetic Polymorphisms of Neurocardiovascular Disorders. in Archives of Medicine. 2015;7(2).
https://hdl.handle.net/21.15107/rcub_vinar_8409 .

Bojić, Tijana, Milovanović, Branislav, Jovanović-Ćupić, Snežana P., "Genetic Polymorphisms of Neurocardiovascular Disorders" in Archives of Medicine, 7, no. 2 (2015),
https://hdl.handle.net/21.15107/rcub_vinar_8409 .

TY  - JOUR
AU  - Jovanović-Ćupić, Snežana P.
AU  - Glišić, Sanja
AU  - Stanojevic, M.
AU  - Vasiljević, N.
AU  - Bojić, Tijana
AU  - Božović, Ana M.
AU  - Dimitrijević, Bogomir B.
PY  - 2014
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/5858
AB  - Hepatitis C virus infection is the most common chronic blood-borne infection and one of the most important causes of chronic liver disease. Knowing the predictors associated with pegylated interferon/ribavirin (PEG-IFN/RBV) combination therapy response is important for evidence-based treatment recommendations. The goal of this study was to identify host and viral factors of response to PEG-IFN/RBV treatment in chronic hepatitis C genotype 1b patients. We have examined the relationship between gender, age, level of alanine aminotransferase (ALT), viral load and liver fibrosis progression on therapy response. ALT level and viral load were evaluated before starting treatment with combination therapy. The elevated levels of ALT and route of HCV transmission were found to be significantly associated with the response to therapy in HCV-infected patients. Our findings may be useful for estimating a patients likelihood Of achieving sustained viral response.
T2  - Archives of Biological Sciences
T1  - Response Factors to Pegylated Interferon-Alfa/Ribavirin Treatment in Chronic Hepatitis C Patients Genotype 1b
VL  - 66
IS  - 1
SP  - 193
EP  - 201
DO  - 10.2298/ABS1401193J
ER  - 

@article{
author = "Jovanović-Ćupić, Snežana P. and Glišić, Sanja and Stanojevic, M. and Vasiljević, N. and Bojić, Tijana and Božović, Ana M. and Dimitrijević, Bogomir B.",
year = "2014",
abstract = "Hepatitis C virus infection is the most common chronic blood-borne infection and one of the most important causes of chronic liver disease. Knowing the predictors associated with pegylated interferon/ribavirin (PEG-IFN/RBV) combination therapy response is important for evidence-based treatment recommendations. The goal of this study was to identify host and viral factors of response to PEG-IFN/RBV treatment in chronic hepatitis C genotype 1b patients. We have examined the relationship between gender, age, level of alanine aminotransferase (ALT), viral load and liver fibrosis progression on therapy response. ALT level and viral load were evaluated before starting treatment with combination therapy. The elevated levels of ALT and route of HCV transmission were found to be significantly associated with the response to therapy in HCV-infected patients. Our findings may be useful for estimating a patients likelihood Of achieving sustained viral response.",
journal = "Archives of Biological Sciences",
title = "Response Factors to Pegylated Interferon-Alfa/Ribavirin Treatment in Chronic Hepatitis C Patients Genotype 1b",
volume = "66",
number = "1",
pages = "193-201",
doi = "10.2298/ABS1401193J"
}

Jovanović-Ćupić, S. P., Glišić, S., Stanojevic, M., Vasiljević, N., Bojić, T., Božović, A. M.,& Dimitrijević, B. B.. (2014). Response Factors to Pegylated Interferon-Alfa/Ribavirin Treatment in Chronic Hepatitis C Patients Genotype 1b. in Archives of Biological Sciences, 66(1), 193-201.
https://doi.org/10.2298/ABS1401193J

Jovanović-Ćupić SP, Glišić S, Stanojevic M, Vasiljević N, Bojić T, Božović AM, Dimitrijević BB. Response Factors to Pegylated Interferon-Alfa/Ribavirin Treatment in Chronic Hepatitis C Patients Genotype 1b. in Archives of Biological Sciences. 2014;66(1):193-201.
doi:10.2298/ABS1401193J .

Jovanović-Ćupić, Snežana P., Glišić, Sanja, Stanojevic, M., Vasiljević, N., Bojić, Tijana, Božović, Ana M., Dimitrijević, Bogomir B., "Response Factors to Pegylated Interferon-Alfa/Ribavirin Treatment in Chronic Hepatitis C Patients Genotype 1b" in Archives of Biological Sciences, 66, no. 1 (2014):193-201,
https://doi.org/10.2298/ABS1401193J . .

TY  - JOUR
AU  - Božović, Ana M.
AU  - Markićević, Milan
AU  - Dimitrijević, Bogomir B.
AU  - Jovanović-Ćupić, Snežana P.
AU  - Krajnović, Milena M.
AU  - Lukić, Silvana
AU  - Mandušić, Vesna
PY  - 2013
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/5647
AB  - The aim of the study was to assess how hypermethylation of the ON promoter of the estrogen receptor beta (ER beta) gene affects its expression (at the mRNA and protein level) and to correlate these with some clinical and histopathological parameters. A total of 131 samples of frozen breast cancer tissue was analyzed. A custom-designed, two-step PCR method was used to measure the methylation index of the ER beta gene ON promoter region. Quantitative reverse transcriptase-polymerase chain reaction (qRT-PCR) was performed to quantify mRNA of the ER beta 1 isoform, while ER beta 1 protein was determined using the Western blot method. There was a significant difference in the methylation index of the ER beta gene ON promoter between the groups of patients with negative and positive axillary lymph node status (P = 0.03). In addition, the methylation index of the ON promoter was positively correlated with estrogen receptor alfa (ER alpha) protein levels (q = 0.31, P = 0.02). There was a significant difference in the methylation index of the ON promoter between the progesterone receptor (PR)-negative and PR-positive groups of patients (P = 0.01). ER beta 1 protein levels were negatively correlated with ER alpha protein (q = -0.27, P LT 0.01). The methylation index of the ON promoter could be a more reliable additional parameter for prediction and/or prognosis in breast cancer than ER beta 1-mRNA and/or protein levels.
T2  - Medical Oncology
T1  - Potential clinical significance of ER beta ON promoter methylation in sporadic breast cancer
VL  - 30
IS  - 3
DO  - 10.1007/s12032-013-0642-4
ER  - 

@article{
author = "Božović, Ana M. and Markićević, Milan and Dimitrijević, Bogomir B. and Jovanović-Ćupić, Snežana P. and Krajnović, Milena M. and Lukić, Silvana and Mandušić, Vesna",
year = "2013",
abstract = "The aim of the study was to assess how hypermethylation of the ON promoter of the estrogen receptor beta (ER beta) gene affects its expression (at the mRNA and protein level) and to correlate these with some clinical and histopathological parameters. A total of 131 samples of frozen breast cancer tissue was analyzed. A custom-designed, two-step PCR method was used to measure the methylation index of the ER beta gene ON promoter region. Quantitative reverse transcriptase-polymerase chain reaction (qRT-PCR) was performed to quantify mRNA of the ER beta 1 isoform, while ER beta 1 protein was determined using the Western blot method. There was a significant difference in the methylation index of the ER beta gene ON promoter between the groups of patients with negative and positive axillary lymph node status (P = 0.03). In addition, the methylation index of the ON promoter was positively correlated with estrogen receptor alfa (ER alpha) protein levels (q = 0.31, P = 0.02). There was a significant difference in the methylation index of the ON promoter between the progesterone receptor (PR)-negative and PR-positive groups of patients (P = 0.01). ER beta 1 protein levels were negatively correlated with ER alpha protein (q = -0.27, P LT 0.01). The methylation index of the ON promoter could be a more reliable additional parameter for prediction and/or prognosis in breast cancer than ER beta 1-mRNA and/or protein levels.",
journal = "Medical Oncology",
title = "Potential clinical significance of ER beta ON promoter methylation in sporadic breast cancer",
volume = "30",
number = "3",
doi = "10.1007/s12032-013-0642-4"
}

Božović, A. M., Markićević, M., Dimitrijević, B. B., Jovanović-Ćupić, S. P., Krajnović, M. M., Lukić, S.,& Mandušić, V.. (2013). Potential clinical significance of ER beta ON promoter methylation in sporadic breast cancer. in Medical Oncology, 30(3).
https://doi.org/10.1007/s12032-013-0642-4

Božović AM, Markićević M, Dimitrijević BB, Jovanović-Ćupić SP, Krajnović MM, Lukić S, Mandušić V. Potential clinical significance of ER beta ON promoter methylation in sporadic breast cancer. in Medical Oncology. 2013;30(3).
doi:10.1007/s12032-013-0642-4 .

Božović, Ana M., Markićević, Milan, Dimitrijević, Bogomir B., Jovanović-Ćupić, Snežana P., Krajnović, Milena M., Lukić, Silvana, Mandušić, Vesna, "Potential clinical significance of ER beta ON promoter methylation in sporadic breast cancer" in Medical Oncology, 30, no. 3 (2013),
https://doi.org/10.1007/s12032-013-0642-4 . .

TY  - JOUR
AU  - Balint, Bela
AU  - Vučetić, Dušan D.
AU  - Todorović-Balint, Milena
AU  - Borovčanin, Nemanja
AU  - Jovanović-Ćupić, Snežana P.
AU  - Mandušić, Vesna
PY  - 2013
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/5682
T2  - Transfusion and Apheresis Science
T1  - Safety improving by complementary serological and molecular testing combined with pathogen reduction of the donated blood in window period
VL  - 49
IS  - 1
SP  - 103
EP  - 104
DO  - 10.1016/j.transci.2012.09.008
ER  - 

@article{
author = "Balint, Bela and Vučetić, Dušan D. and Todorović-Balint, Milena and Borovčanin, Nemanja and Jovanović-Ćupić, Snežana P. and Mandušić, Vesna",
year = "2013",
journal = "Transfusion and Apheresis Science",
title = "Safety improving by complementary serological and molecular testing combined with pathogen reduction of the donated blood in window period",
volume = "49",
number = "1",
pages = "103-104",
doi = "10.1016/j.transci.2012.09.008"
}

Balint, B., Vučetić, D. D., Todorović-Balint, M., Borovčanin, N., Jovanović-Ćupić, S. P.,& Mandušić, V.. (2013). Safety improving by complementary serological and molecular testing combined with pathogen reduction of the donated blood in window period. in Transfusion and Apheresis Science, 49(1), 103-104.
https://doi.org/10.1016/j.transci.2012.09.008

Balint B, Vučetić DD, Todorović-Balint M, Borovčanin N, Jovanović-Ćupić SP, Mandušić V. Safety improving by complementary serological and molecular testing combined with pathogen reduction of the donated blood in window period. in Transfusion and Apheresis Science. 2013;49(1):103-104.
doi:10.1016/j.transci.2012.09.008 .

Balint, Bela, Vučetić, Dušan D., Todorović-Balint, Milena, Borovčanin, Nemanja, Jovanović-Ćupić, Snežana P., Mandušić, Vesna, "Safety improving by complementary serological and molecular testing combined with pathogen reduction of the donated blood in window period" in Transfusion and Apheresis Science, 49, no. 1 (2013):103-104,
https://doi.org/10.1016/j.transci.2012.09.008 . .

TY  - JOUR
AU  - Glišić, Sanja
AU  - Veljković, Nevena V.
AU  - Jovanović-Ćupić, Snežana P.
AU  - Vasiljevic, Nada
AU  - Prljić, Jelena
AU  - Gemović, Branislava S.
AU  - Perović, Vladimir R.
AU  - Veljković, Veljko
PY  - 2012
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/4755
AB  - Hepatitis C virus (HCV) infection is a major and rising global health problem, affecting about 170 million people worldwide. The current standard of care treatment with interferon alpha and ribavirin in patients with the genotype 1 infection, the most frequent genotype in the USA and Western Europe, leads to a successful outcome in only about 50% of individuals. Accurate prediction of hepatitis C treatment response is of great benefit to patients and clinicians. The informational spectrum method, a virtual spectroscopy method for structure/function analysis of nucleotide and protein sequences, is applied here for the identification of the conserved information of the HCV proteins that correlate with the combination therapy outcome. Among the HCV proteins that we have analyzed the informational property of the p7 of HCV genotype 1b was best related to the therapy outcome. On the basis of these results, a simple bioinformatics criterion that could be useful in assessment of the response of HCV-infected patients to the combination therapy has been proposed.
T2  - Protein Journal
T1  - Assessment of Hepatitis C Virus Protein Sequences with Regard to Interferon/Ribavirin Combination Therapy Response in Patients with HCV Genotype 1b
VL  - 31
IS  - 2
SP  - 129
EP  - 136
DO  - 10.1007/s10930-011-9381-6
ER  - 

@article{
author = "Glišić, Sanja and Veljković, Nevena V. and Jovanović-Ćupić, Snežana P. and Vasiljevic, Nada and Prljić, Jelena and Gemović, Branislava S. and Perović, Vladimir R. and Veljković, Veljko",
year = "2012",
abstract = "Hepatitis C virus (HCV) infection is a major and rising global health problem, affecting about 170 million people worldwide. The current standard of care treatment with interferon alpha and ribavirin in patients with the genotype 1 infection, the most frequent genotype in the USA and Western Europe, leads to a successful outcome in only about 50% of individuals. Accurate prediction of hepatitis C treatment response is of great benefit to patients and clinicians. The informational spectrum method, a virtual spectroscopy method for structure/function analysis of nucleotide and protein sequences, is applied here for the identification of the conserved information of the HCV proteins that correlate with the combination therapy outcome. Among the HCV proteins that we have analyzed the informational property of the p7 of HCV genotype 1b was best related to the therapy outcome. On the basis of these results, a simple bioinformatics criterion that could be useful in assessment of the response of HCV-infected patients to the combination therapy has been proposed.",
journal = "Protein Journal",
title = "Assessment of Hepatitis C Virus Protein Sequences with Regard to Interferon/Ribavirin Combination Therapy Response in Patients with HCV Genotype 1b",
volume = "31",
number = "2",
pages = "129-136",
doi = "10.1007/s10930-011-9381-6"
}

Glišić, S., Veljković, N. V., Jovanović-Ćupić, S. P., Vasiljevic, N., Prljić, J., Gemović, B. S., Perović, V. R.,& Veljković, V.. (2012). Assessment of Hepatitis C Virus Protein Sequences with Regard to Interferon/Ribavirin Combination Therapy Response in Patients with HCV Genotype 1b. in Protein Journal, 31(2), 129-136.
https://doi.org/10.1007/s10930-011-9381-6

Glišić S, Veljković NV, Jovanović-Ćupić SP, Vasiljevic N, Prljić J, Gemović BS, Perović VR, Veljković V. Assessment of Hepatitis C Virus Protein Sequences with Regard to Interferon/Ribavirin Combination Therapy Response in Patients with HCV Genotype 1b. in Protein Journal. 2012;31(2):129-136.
doi:10.1007/s10930-011-9381-6 .

Glišić, Sanja, Veljković, Nevena V., Jovanović-Ćupić, Snežana P., Vasiljevic, Nada, Prljić, Jelena, Gemović, Branislava S., Perović, Vladimir R., Veljković, Veljko, "Assessment of Hepatitis C Virus Protein Sequences with Regard to Interferon/Ribavirin Combination Therapy Response in Patients with HCV Genotype 1b" in Protein Journal, 31, no. 2 (2012):129-136,
https://doi.org/10.1007/s10930-011-9381-6 . .

TY  - THES
AU  - Jovanović-Ćupić, Snežana P.
PY  - 2012
UR  - http://eteze.bg.ac.rs/application/showtheses?thesesId=35
UR  - https://fedorabg.bg.ac.rs/fedora/get/o:2323/bdef:Content/download
UR  - http://vbs.rs/scripts/cobiss?command=DISPLAY&base=70036&RID=41538575
UR  - http://nardus.mpn.gov.rs/123456789/2028
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/7239
AB  - Uvod: Infekcija virusom hepatitisa C (HCV) predstavlja značajan globalni zdravstveni problem koji često vodi ka hroničnoj bolesti jetre i cirozi. Prema podacima Svetske zdravstvene organizacije registrovano je preko 170 miliona ljudi inficiranih virusom HCV. Sadašnja standardna terapija hroničnog HCV-a kod pacijenata inficiranih genotipom 1b, koji predstavlja najčešći genotip kako u SAD, zapadnoj Evropi i Srbiji, se sastoji od pegilovanog interferona u kombinaciji sa ribavirinom. Međutim, kombinovana terapija je praćena brojnim neželjenim efektima i dovodi do stabilnog virusološkog odgovora samo kod 50% pacijenata inficiranih genotipom 1. Stoga bi jednostavan i pouzdan test, koji bi pre početka terapije mogao da predvidi virusološki odgovor, bio od velike koristi u kliničkoj praksi. Metode: Identifikacija konzervirane informacije sadržane u proteinima HCV koja korelira sa odgovorom na standardnu kombinovanu terapiju rađena je bioinformatičkom analizom. Uzorci plazme 48 pacijenata sa hroničnom infekcijom HCV, genotipa 1b su klasifikovani u odnosu na odgovor na kombinovanu terapiju. Za određivanje primarne strukture proteina HCV primenjene su klasične metode molekularne biologije: reverzna transkripcija i lančana reakcija polimeraze (Rt-PCR), apsolutna kvantifikacija sa PCR-om u realnom vremenu i automatsko sekvenciranje. Rezultati: Na osnovu rezultata analize svih proteina virusa HCV utvrđeno je da je informacioni sadržaj proteina p7 u korelаciji sа odgovorom nа kombinovаnu terаpiju. Rezultati dobijeni analizom proteinskih sekvenci, 48 pacijenata sa teritorije Srbije su u saglasnosti sa predloženim bioinformatičkim kriterijumom. Posebna pažnja je posvećena optimizaciji eksperimentalnih protokola i formiranju homogenenih grupa u odnosu na osobenosti virusa (tip i podtip) i odgovora na antivirusnu terapiju pacijenata. Zaključak: Na osnovu rezultata ove studije predložen je bioinformatički kriterijum koji omogućаvа procenu odgovora hroničnih HCV bolesnikа inficirаnih genotipom 1b nа kombinovаnu terаpiju.
AB  - Background: Hepatitis C virus (HCV) infection is a major and rising global health problem, affecting about 170 million people worldwide, according to WHO data, and often leading to chronic liver disease and cirrhosis. The current standard therapy for chronic HCV infection with pegylated interferon combined with ribavirin in patients with the genotype 1 infection, the most frequent genotype in the USA, Western Europe and Serbia, accompanied by numerous side effects, leads to a successful outcome in only about 50% of individuals. Therefore, simple and accurate prediction of hepatitis C treatment response is of great benefit to patients and clinicians. Methods: Identification of the conserved information of the HCV proteins that correlate with the combination therapy outcome was performed by bioinformatics analysis. Plasma samples of 48 chronic HCV patients from Serbia were classified according to the outcome of therapy. To determine primary structure of HCV proteins classical methods of molecular biology: reverse transcription and polymerase chain reaction (Rt-PCR), the absolute quantification-Real Time PCR and DNA sequencing were applied. Results: Among the HCV proteins that we have analyzed the informational property of the p7 of HCV genotype 1b was best related to the therapy outcome. Findings obtained from analyzing sequences 48 patients collected from Serbia were in perfect agreement with proposed bioinformatics criterion. Special attention was paid to optimization experimental protocols and forming homogeneous groups of patients regarding HCV genotype (type and subtype) and therapy response. Conclusions: On the basis of the results in the present study, a simple bioinformatics criterion that could be useful in assessment of the response of HCV-infected patients to the combination therapy has been proposed.
PB  - Универзитет у Београду, Биолошки факултет
T2  - Универзитет у Београду
T1  - Konzervirana svojstva proteina virusa hepatitisa C genotipa 1b kao prognostičkih markera odgovora na kombinovanu terapiju pegilovanim interferonom i ribavirinom
T1  - Conserved properties of hepatitis C genotype 1b proteinsas prognostic markers of response to pegylated interferon and ribavirin combination therapy
UR  - https://hdl.handle.net/21.15107/rcub_nardus_2028
ER  - 

@phdthesis{
author = "Jovanović-Ćupić, Snežana P.",
year = "2012",
abstract = "Uvod: Infekcija virusom hepatitisa C (HCV) predstavlja značajan globalni zdravstveni problem koji često vodi ka hroničnoj bolesti jetre i cirozi. Prema podacima Svetske zdravstvene organizacije registrovano je preko 170 miliona ljudi inficiranih virusom HCV. Sadašnja standardna terapija hroničnog HCV-a kod pacijenata inficiranih genotipom 1b, koji predstavlja najčešći genotip kako u SAD, zapadnoj Evropi i Srbiji, se sastoji od pegilovanog interferona u kombinaciji sa ribavirinom. Međutim, kombinovana terapija je praćena brojnim neželjenim efektima i dovodi do stabilnog virusološkog odgovora samo kod 50% pacijenata inficiranih genotipom 1. Stoga bi jednostavan i pouzdan test, koji bi pre početka terapije mogao da predvidi virusološki odgovor, bio od velike koristi u kliničkoj praksi. Metode: Identifikacija konzervirane informacije sadržane u proteinima HCV koja korelira sa odgovorom na standardnu kombinovanu terapiju rađena je bioinformatičkom analizom. Uzorci plazme 48 pacijenata sa hroničnom infekcijom HCV, genotipa 1b su klasifikovani u odnosu na odgovor na kombinovanu terapiju. Za određivanje primarne strukture proteina HCV primenjene su klasične metode molekularne biologije: reverzna transkripcija i lančana reakcija polimeraze (Rt-PCR), apsolutna kvantifikacija sa PCR-om u realnom vremenu i automatsko sekvenciranje. Rezultati: Na osnovu rezultata analize svih proteina virusa HCV utvrđeno je da je informacioni sadržaj proteina p7 u korelаciji sа odgovorom nа kombinovаnu terаpiju. Rezultati dobijeni analizom proteinskih sekvenci, 48 pacijenata sa teritorije Srbije su u saglasnosti sa predloženim bioinformatičkim kriterijumom. Posebna pažnja je posvećena optimizaciji eksperimentalnih protokola i formiranju homogenenih grupa u odnosu na osobenosti virusa (tip i podtip) i odgovora na antivirusnu terapiju pacijenata. Zaključak: Na osnovu rezultata ove studije predložen je bioinformatički kriterijum koji omogućаvа procenu odgovora hroničnih HCV bolesnikа inficirаnih genotipom 1b nа kombinovаnu terаpiju., Background: Hepatitis C virus (HCV) infection is a major and rising global health problem, affecting about 170 million people worldwide, according to WHO data, and often leading to chronic liver disease and cirrhosis. The current standard therapy for chronic HCV infection with pegylated interferon combined with ribavirin in patients with the genotype 1 infection, the most frequent genotype in the USA, Western Europe and Serbia, accompanied by numerous side effects, leads to a successful outcome in only about 50% of individuals. Therefore, simple and accurate prediction of hepatitis C treatment response is of great benefit to patients and clinicians. Methods: Identification of the conserved information of the HCV proteins that correlate with the combination therapy outcome was performed by bioinformatics analysis. Plasma samples of 48 chronic HCV patients from Serbia were classified according to the outcome of therapy. To determine primary structure of HCV proteins classical methods of molecular biology: reverse transcription and polymerase chain reaction (Rt-PCR), the absolute quantification-Real Time PCR and DNA sequencing were applied. Results: Among the HCV proteins that we have analyzed the informational property of the p7 of HCV genotype 1b was best related to the therapy outcome. Findings obtained from analyzing sequences 48 patients collected from Serbia were in perfect agreement with proposed bioinformatics criterion. Special attention was paid to optimization experimental protocols and forming homogeneous groups of patients regarding HCV genotype (type and subtype) and therapy response. Conclusions: On the basis of the results in the present study, a simple bioinformatics criterion that could be useful in assessment of the response of HCV-infected patients to the combination therapy has been proposed.",
publisher = "Универзитет у Београду, Биолошки факултет",
journal = "Универзитет у Београду",
title = "Konzervirana svojstva proteina virusa hepatitisa C genotipa 1b kao prognostičkih markera odgovora na kombinovanu terapiju pegilovanim interferonom i ribavirinom, Conserved properties of hepatitis C genotype 1b proteinsas prognostic markers of response to pegylated interferon and ribavirin combination therapy",
url = "https://hdl.handle.net/21.15107/rcub_nardus_2028"
}

Jovanović-Ćupić, S. P.. (2012). Konzervirana svojstva proteina virusa hepatitisa C genotipa 1b kao prognostičkih markera odgovora na kombinovanu terapiju pegilovanim interferonom i ribavirinom. in Универзитет у Београду
Универзитет у Београду, Биолошки факултет..
https://hdl.handle.net/21.15107/rcub_nardus_2028

Jovanović-Ćupić SP. Konzervirana svojstva proteina virusa hepatitisa C genotipa 1b kao prognostičkih markera odgovora na kombinovanu terapiju pegilovanim interferonom i ribavirinom. in Универзитет у Београду. 2012;.
https://hdl.handle.net/21.15107/rcub_nardus_2028 .

Jovanović-Ćupić, Snežana P., "Konzervirana svojstva proteina virusa hepatitisa C genotipa 1b kao prognostičkih markera odgovora na kombinovanu terapiju pegilovanim interferonom i ribavirinom" in Универзитет у Београду (2012),
https://hdl.handle.net/21.15107/rcub_nardus_2028 .

TY  - CONF
AU  - Vasiljević, N.
AU  - Veljković, Nevena V.
AU  - Jovanović-Ćupić, Snežana P.
AU  - Glišić, Sanja
PY  - 2010
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/4043
AB  - Background:Numerous studies have reported a relationship betweenhepatitis C virus (HCV) genotype and the response to interferon therapy.Despite high sensitivity and specificity, genotyping methods can be per-formed only on HCV RNA positive samples. Serotyping might be a rapidand cost effective method for determining HCV genotypes, especially inpatients with previously undetectable HCV RNA.Aim:The aim of this study was to select NS5A-derived peptides whichmay represent candidate specific markers for determination of HCVgenotypes by serotyping.Methods:The conserved structural and informational properties of HCVNS5A protein have been determined by the informational spectrum method(ISM), representing virtual spectroscopy method for analysis of relationshipbetween structure and function of proteins.Results:The ISM analysis revealed that NS5A proteins from HCV geno-types 1,2,3,4 and 6 encode the conserved information which is specific foreasch particular genotype, and which is represented by IS frequenciesF1(0.258), F2(0.271), F3(0.053), F4(0.205) and F6(0.146), respectively. TheNS5-derived peptides P1(120-152), P2(383-417), P3(405-439), P4(171-205), P6(374-408) are identified as domains that are essential for conservedinformation characterizing HCV genotypes 1, 2, 3, 4 and 6.Conclusions:Peptides P1, P2, P3, P4 and P6 derived from NS5A proteinrepresent candidate markers for simple and fast identification of HCVgenotypes by serotyping
C3  - Vox Sanguinis
T1  - Selection of Ns5a-Derived Peptides for Determination of Hcv Genotypes By Serotyping
VL  - 99
IS  - Supp: 1
SP  - 299
DO  - 10.1111/j.1423-0410.2010.01343_2.x
UR  - https://hdl.handle.net/21.15107/rcub_vinar_4043
ER  - 

@conference{
author = "Vasiljević, N. and Veljković, Nevena V. and Jovanović-Ćupić, Snežana P. and Glišić, Sanja",
year = "2010",
abstract = "Background:Numerous studies have reported a relationship betweenhepatitis C virus (HCV) genotype and the response to interferon therapy.Despite high sensitivity and specificity, genotyping methods can be per-formed only on HCV RNA positive samples. Serotyping might be a rapidand cost effective method for determining HCV genotypes, especially inpatients with previously undetectable HCV RNA.Aim:The aim of this study was to select NS5A-derived peptides whichmay represent candidate specific markers for determination of HCVgenotypes by serotyping.Methods:The conserved structural and informational properties of HCVNS5A protein have been determined by the informational spectrum method(ISM), representing virtual spectroscopy method for analysis of relationshipbetween structure and function of proteins.Results:The ISM analysis revealed that NS5A proteins from HCV geno-types 1,2,3,4 and 6 encode the conserved information which is specific foreasch particular genotype, and which is represented by IS frequenciesF1(0.258), F2(0.271), F3(0.053), F4(0.205) and F6(0.146), respectively. TheNS5-derived peptides P1(120-152), P2(383-417), P3(405-439), P4(171-205), P6(374-408) are identified as domains that are essential for conservedinformation characterizing HCV genotypes 1, 2, 3, 4 and 6.Conclusions:Peptides P1, P2, P3, P4 and P6 derived from NS5A proteinrepresent candidate markers for simple and fast identification of HCVgenotypes by serotyping",
journal = "Vox Sanguinis",
title = "Selection of Ns5a-Derived Peptides for Determination of Hcv Genotypes By Serotyping",
volume = "99",
number = "Supp: 1",
pages = "299",
doi = "10.1111/j.1423-0410.2010.01343_2.x",
url = "https://hdl.handle.net/21.15107/rcub_vinar_4043"
}

Vasiljević, N., Veljković, N. V., Jovanović-Ćupić, S. P.,& Glišić, S.. (2010). Selection of Ns5a-Derived Peptides for Determination of Hcv Genotypes By Serotyping. in Vox Sanguinis, 99(Supp: 1), 299.
https://doi.org/10.1111/j.1423-0410.2010.01343_2.x
https://hdl.handle.net/21.15107/rcub_vinar_4043

Vasiljević N, Veljković NV, Jovanović-Ćupić SP, Glišić S. Selection of Ns5a-Derived Peptides for Determination of Hcv Genotypes By Serotyping. in Vox Sanguinis. 2010;99(Supp: 1):299.
doi:10.1111/j.1423-0410.2010.01343_2.x
https://hdl.handle.net/21.15107/rcub_vinar_4043 .

Vasiljević, N., Veljković, Nevena V., Jovanović-Ćupić, Snežana P., Glišić, Sanja, "Selection of Ns5a-Derived Peptides for Determination of Hcv Genotypes By Serotyping" in Vox Sanguinis, 99, no. Supp: 1 (2010):299,
https://doi.org/10.1111/j.1423-0410.2010.01343_2.x .,
https://hdl.handle.net/21.15107/rcub_vinar_4043 .

TY  - JOUR
AU  - Jovanović-Ćupić, Snežana P.
AU  - Simonovic-Babic, Jasmina
AU  - Blagojevic, Jelena
AU  - Božić, Milena
AU  - Ješić, Rada
AU  - Nozic, D.
AU  - Stamenković, Gorana
PY  - 2009
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/3752
AB  - Different types of interferon are widely used to treat hepatitis C virus (HCV) infection. Results obtained in vitro suggest that interferon inhibits internal ribosome entry site (IRES)-mediated translation of the HCV genome. To elucidate the possible effect of the nucleotide sequence of IRES on therapy outcome, we compared HCV isolates from patients with sustained response and non-response to interferon/ribavirin combination therapy. In 56 analyzed HCV isolates, nucleotide changes appeared strictly in the stem-loop IIIb region, the stem part from 243 nt to 248 nt, and the polypyrimidine-II region. The natural sequence variability of IRES in isolates of genotype 3a was significantly higher than in isolates of genotype 1b (p LT 0.05). The average number of nucleotide changes in genotype 3a correlated with response to therapy (p LT 0.05).
T2  - Archives of Biological Sciences
T1  - Sequence Variability At the Internal Ribosome Entry Site of the Hcv Genome in Relation to Therapy Outcome
VL  - 61
IS  - 2
SP  - 205
EP  - 212
DO  - 10.2298/ABS0901205J
ER  - 

@article{
author = "Jovanović-Ćupić, Snežana P. and Simonovic-Babic, Jasmina and Blagojevic, Jelena and Božić, Milena and Ješić, Rada and Nozic, D. and Stamenković, Gorana",
year = "2009",
abstract = "Different types of interferon are widely used to treat hepatitis C virus (HCV) infection. Results obtained in vitro suggest that interferon inhibits internal ribosome entry site (IRES)-mediated translation of the HCV genome. To elucidate the possible effect of the nucleotide sequence of IRES on therapy outcome, we compared HCV isolates from patients with sustained response and non-response to interferon/ribavirin combination therapy. In 56 analyzed HCV isolates, nucleotide changes appeared strictly in the stem-loop IIIb region, the stem part from 243 nt to 248 nt, and the polypyrimidine-II region. The natural sequence variability of IRES in isolates of genotype 3a was significantly higher than in isolates of genotype 1b (p LT 0.05). The average number of nucleotide changes in genotype 3a correlated with response to therapy (p LT 0.05).",
journal = "Archives of Biological Sciences",
title = "Sequence Variability At the Internal Ribosome Entry Site of the Hcv Genome in Relation to Therapy Outcome",
volume = "61",
number = "2",
pages = "205-212",
doi = "10.2298/ABS0901205J"
}

Jovanović-Ćupić, S. P., Simonovic-Babic, J., Blagojevic, J., Božić, M., Ješić, R., Nozic, D.,& Stamenković, G.. (2009). Sequence Variability At the Internal Ribosome Entry Site of the Hcv Genome in Relation to Therapy Outcome. in Archives of Biological Sciences, 61(2), 205-212.
https://doi.org/10.2298/ABS0901205J

Jovanović-Ćupić SP, Simonovic-Babic J, Blagojevic J, Božić M, Ješić R, Nozic D, Stamenković G. Sequence Variability At the Internal Ribosome Entry Site of the Hcv Genome in Relation to Therapy Outcome. in Archives of Biological Sciences. 2009;61(2):205-212.
doi:10.2298/ABS0901205J .

Jovanović-Ćupić, Snežana P., Simonovic-Babic, Jasmina, Blagojevic, Jelena, Božić, Milena, Ješić, Rada, Nozic, D., Stamenković, Gorana, "Sequence Variability At the Internal Ribosome Entry Site of the Hcv Genome in Relation to Therapy Outcome" in Archives of Biological Sciences, 61, no. 2 (2009):205-212,
https://doi.org/10.2298/ABS0901205J . .